Last updated: 06/2021

Contributor(s): Dr. Maureen Williams, ND; Dr. Shayna Sandhaus, PhD

1 Overview

Summary and Quick Facts

  • The flu is a common respiratory infection caused by the influenza virus. Although the flu usually resolves on its own, it may progress to serious problems like pneumonia, especially in older people or people with suppressed immune systems.
  • It is imperative that appropriate treatment be initiated as soon as possible after the first symptoms of the flu emerge. Antiviral drugs that may reduce the duration of the flu, such as Tamiflu and Xofluza, may be less effective if not initiated rapidly upon symptom onset. Importantly, antibiotics will not help the flu.
  • Because influenza viruses continually mutate, annual vaccination is recommended.
  • Nutrients such as vitamin D and zinc support healthy immune function and have been shown to decrease risk of infections, such as colds and the flu.
  • Some clinical evidence suggests herbal supplements such as elderberry and andrographis may decrease the severity and duration of influenza.

What is the Flu?

The flu, which can be caused by several strains of influenza, is a highly contagious and potentially deadly viral infection that affects the upper and lower airways. Most cases resolve without treatment within two weeks. However, if left untreated, severe complications can arise, especially in high-risk groups (eg, the elderly, people with existing medical conditions, those with compromised immune function, etc.).

What are the Signs and Symptoms of the Flu?

  • Sudden onset of high fever
  • Fatigue
  • Head and body aches
  • Cough, congestion
  • Sore throat

Note: The flu can be distinguished from a common cold by severity of symptoms and speed of symptom onset: cold symptoms are generally mild and develop over several days, while flu symptoms are much more severe and develop more rapidly.

How Can the Flu be Prevented?

  • Get vaccinated yearly for the flu. While this does not guarantee immunity, it is the most effective and least expensive medical intervention. Influenza viruses continually mutate, making annual vaccination essential for continued protection.
  • Exercise regularly and eat a balanced diet.
  • Gargle with water and use saline nasal drops or nasal irrigation regularly.
  • Wash or sanitize hands and surfaces frequently.
  • Avoid touching your eyes, nose, and mouth with unwashed hands.
  • Avoid sick people when possible or wear a face mask.
  • Protect others by staying home when you are sick, coughing or sneezing into the crook of your elbow (rather than your hand or the air), and wearing a face mask when you have flu symptoms.

How is the Flu Treated?

  • DO NOT take antibiotics for the flu. Antibiotics do not kill influenza viruses and can contribute to the development of drug-resistant bacteria.
  • Over-the-counter drugs (eg, mild analgesics, decongestants, etc.) can provide symptomatic relief for uncomplicated cases of the flu.
  • Antiviral drugs are mainly used to treat patients at high risk of developing flu complications. Currently, there are only two oral antiviral drugs being prescribed to treat the flu:
    • Oseltamivir (Tamiflu)
    • Baloxavir marboxil (Xofluza)

Top Nutrients for the Flu

  • Probiotics. Probiotic supplements, especially those containing species of Lactobacillus and Bifidobacterium, have been found to reduce the incidence and severity of upper respiratory viral infections, including the flu.
  • Ginseng. Ginseng extracts have been shown to activate the antiviral immune response while reducing the inflammatory response, and clinical trials suggest it may lower the risk of the flu and improve the immune response to the flu vaccine.
  • Green tea. Green tea catechins have demonstrated antiviral actions against influenza and other respiratory viruses. Green tea may help prevent viral respiratory infections and may decrease flu-like symptoms by reducing inflammation.
  • Elderberry. Clinical research indicates elderberry extract, rich in anti-inflammatory and antioxidant polyphenols, may reduce influenza symptoms and shorten duration of illness when started within 48 hours of symptom onset.
  • Andrographis. Multiple randomized controlled trials and two meta-analyses have found andrographis extract, alone and in herbal combinations, reduced symptoms of upper respiratory tract infections and may be especially helpful in alleviating cough and sore throat.

2 Introduction

Influenza (the flu), an acute viral respiratory infection caused by influenza A and B viruses, is easily transmitted from person to person.1,2 Most people who contract influenza have upper respiratory symptoms that resolve without treatment, but influenza can also involve the lower respiratory tract causing complications like bronchitis and pneumonia, particularly in the very young, the elderly, and those with chronic diseases.3 In addition, influenza can lead to complications involving the muscles, heart, and nervous system.2

Influenza infections cause substantial illness and death every year worldwide. In places with temperate climates, such as the United States, influenza infections spike in the winter months causing seasonal epidemics.3 The virulence of influenza viruses vary from year to year due to rapid genetic mutation.4 In the past decade, seasonal flu in the United States has been responsible for an estimated 9.3‒454 million illnesses, 140,000‒810,000 hospitalizations, and 12,000‒61,000 deaths per year.5 Worldwide, influenza epidemics cause about one billion infections, 3–5 million cases of severe illness, and 300,000–500,000 deaths per year.4 In addition, from time to time, new influenza viruses emerge and spread rapidly around the globe causing devastating pandemics.

The flu is usually recognizable by the abrupt onset and intensity of its symptoms, but its symptoms can overlap with those of the common cold.1 In some cases, tests may be needed to secure an accurate diagnosis and initiate appropriate isolation measures and therapies as soon as possible.6 Preventive measures such as hand hygiene and mask wearing, especially when adhered to by a large proportion of a population, can go a long way toward reducing the spread of influenza. Annual flu vaccines provide additional protection, with the greatest benefit in people in higher-risk groups such as the elderly, those with chronic illnesses, and those with compromised immune function.7,8 Because uncomplicated influenza resolves without treatment, the use of antiviral medications such as oseltamivir (Tamiflu) is generally reserved for those at higher risk of severe disease and complications. Antibiotics are not effective against influenza viral infection; they are only useful if secondary bacterial infections occur.9

Influenza takes a disproportionate toll on people over 65 years old, largely due to an age-related deterioration in immune function known as immune senescence.10 Immune senescence, a phenomenon associated even with healthy aging, is characterized by decreased antimicrobial defenses and disordered immune signaling. Not only does immune senescence increase susceptibility to severe influenza and its most dangerous complications, but it also decreases the effectiveness of vaccination.11,12 Integrative therapies that enhance antiviral immune activity and modulate inflammatory signaling may help reduce the incidence and severity of influenza. Some natural therapies have been found to directly inhibit viral infection. Probiotics, vitamins C, D, and E, and extracts from medicinal herbs such as ginseng, green tea, andrographis, and elderberry have shown promise for reducing the burden of influenza.

In this protocol, you will learn about influenza viruses and the immune response to influenza infection, as well as how to tell if you are likely to have the flu and what preventive and treatment options are available. The protocol also discusses evidence regarding the repurposing of well-known drugs like statins and antidiabetic medications to help fight influenza. In addition, you will learn about emerging research regarding new antiviral medications, convalescent plasma, and universal vaccines. Finally, this protocol outlines some of the nutrients that may help prevent and treat influenza.

Readers of this protocol may also find useful information in the Pneumonia and Immune Senescence protocols.

If you are reading this because you have developed symptoms consistent with an acute respiratory infection, it is critical that you act quickly to halt the rapid replication of viruses occurring in your body at this very moment. Go to the nearest health food store or pharmacy and purchase:

  1. Probiotics and Postbiotics: Take one capsule daily containing Lactobacillus rhamnosus CRL-1505 and dried fermentate of Saccharomyces cerevisiae.
  2. Black elderberry extract: Chew one tablet containing 90 mg of black elderberry extract eight times daily for five days.
  3. Zinc Lozenges: Completely dissolve in mouth one lozenge containing 18.75 mg of zinc, in the form of zinc gluconate, oxide, or acetate, every 2‒3 waking hours, up to five times per day acutely.
  4. Lactoferrin: Take 150–300 mg of bovine apolactoferrin daily.
  5. Vitamin D: If you do not already maintain a blood level of 25-hydroxyvitamin D over 50 ng/mL, then take 250 mcg (10,000 IU) vitamin D the first day and continue for three more days; then reduce the dose to 50–125 mcg (2,000–5,000 IU) vitamin D each day. If you already take 2,000–5,000 IU vitamin D daily, then you probably do not need to increase your intake.
  6. Melatonin: Take 3‒50 mg at bedtime
  7. Tamiflu: Take 75 mg twice daily. This is a prescription drug and is only effective for certain flu viruses.
  8. Cimetidine: Take 800‒1,200 mg cimetidine daily in divided doses. Cimetidine is a heartburn drug that has potent immune-enhancing properties. (It is sold in pharmacies over-the-counter.) Note: cimetidine can interact with many drugs and potentially cause adverse effects. Talk with a qualified healthcare provider or pharmacist before starting cimetidine to be sure you do not take any drugs that could interact with cimetidine.

Do not delay implementing the above regimen. Once a respiratory virus infects too many cells, it replicates out of control and strategies like zinc lozenges will not be effective. Treatment must be initiated as soon as symptoms manifest!

3 Background

Influenza viruses are categorized into four major types: influenza A, B, C, and D viruses. Influenza A and B viruses cause substantial illness in humans, while influenza C usually causes mild or asymptomatic infections. Influenza D viruses, discovered in 2011, do not appear to cause substantial disease in humans.4

Influenza A viruses are the main cause of serious influenza illness and are responsible for important epidemics and pandemics throughout history.4,13 They exist not only in humans but also domestic animals (swine and poultry) and wild birds (ducks, geese, swans, gulls, and others), which can act as reservoirs.4 Although cats, dogs, and horses can also contract influenza viruses, little to no transmission from these animals to humans has been reported.13

Two proteins on the surface of influenza A viruses, haemagglutinin (which aids viral entry into cells) and neuraminidase (which aids in the release of viral genetic material), are especially variable and are used to classify influenza A viruses into subtypes. There are 18 haemagglutinin (H) and 11 neuraminidase (N) known protein variants.13,14 Currently, influenza A H1N1 and influenza A H3N2 are the subtypes circulating among the human population. In addition, there are two lineages of influenza B virus currently circulating in humans. Annual flu vaccines target both circulating influenza A subtypes plus one or both of the circulating influenza B lineages.4

Influenza A virus subtypes evolve rapidly in response to environmental, immune, and other pressures. Small adaptive mutations in viral genetic material, known as “antigenic drift,” produce new but closely related viruses. Influenza virus strains generated through antigenic drift are susceptible to varying degrees of immune cross-recognition and result in annual influenza outbreaks that vary in transmissibility and severity.14-16 Influenza B viruses, on the other hand, have less tendency to undergo genetic mutation from year to year.14

Influenza A viruses also evolve through large changes in their genetic material known as “antigenic shift.” This can occur when a new virus is mutated enough that it transfers from another animal species, usually domesticated swine or poultry, to humans.4,13,14 Antigenic shift involves the reassortment of segments of genetic material between distinct influenza viruses simultaneously infecting the same cell.14 This produces a new strain of influenza virus that is very different from previous strains. In rare instances when such a novel viral strain is or becomes well adapted for survival in the human host, the lack of immune memory needed to generate a swift and efficient response can pave the way for rapid spread of infection and high rates of severe illness and death.17-19 These viruses have historically caused pandemics that severely impacted not only the very young and very old, but also young adults. However, in subsequent years seasonal outbreaks were more typical.4,14

Influenza Pandemics Throughout History

Influenza viruses have been causing pandemics—infections that spread rapidly around the world with high rates of transmission and mortality—in humans for a very long time. A large outbreak of respiratory illness resembling influenza was first described by Hippocrates in 412 B.C. In the 16th century, an influenza pandemic was clearly documented for the first time. The name “influenza” was given to the illness around this time, based on the Latin word influentia, meaning influence, since it was thought to be due to a bad influence sent from the heavens. Since then, at least 31 influenza pandemics are known to have occurred.

There have been four influenza pandemics since the beginning of the 20th century, and all have been caused by influenza A viruses. The first and deadliest began in 1918 and took the lives of as many as 50–100 million people around the globe. The pathogen was an H1N1 subtype of influenza A virus, and although it is often referred to as the Spanish flu, its origins remain a mystery. Some evidence suggests the first infections may have occurred in China, but the first reports of rapidly spreading illness come from the United States. Additional historical records point to its possible introduction to Europe via Chinese laborers on their way to North America to help with the war effort and/or US soldiers travelling to Europe to fight in the First World War.20

A novel influenza A H2N2 virus was responsible for the pandemic of 1957, known as the Asian flu, and an influenza A H3N2 virus emerged to cause the so-called Hong Kong pandemic of 1968.4 These mid-century influenza pandemics are each blamed for approximately 1–2 million deaths.20 Although an influenza A H1N1 strain began circulating again in 1977, it was similar enough to the preceding H1N1 strain that it did not result in a pandemic.4,20 This was not the case in 2009, when a very different strain of influenza A H1N1 appeared in humans. With little pre-existing immunity in the world population, it spread quickly and caused a pandemic called the Swine flu that killed an estimated 284,000-574,000 people. In contrast to typical annual flu outbreaks, most of the victims of the 2009 pandemic were under 65 years of age.20

4 Risk Factors

The following populations are at higher risk of developing severe seasonal influenza and its complications3,21:

  • Those under 5 and over 65 years of age
  • Nursing home residents
  • People with chronic lung or heart diseases or other chronic medical conditions
  • People taking glucocorticoids or other immune-suppressive medications
  • Immunocompromised individuals
  • Extremely obese individuals
  • Current or past smokers
  • Pregnant women and those who recently gave birth
  • Native Americans, Native Alaskans, and possibly other Indigenous people

Influenza pandemics, unlike seasonal influenza, have notably been associated with higher rates of severe disease, hospitalization, and death in otherwise healthy young adults.21 It is thought immune memory formed during previous exposure to similar virus strains may have given older individuals partial immunity against pandemic influenza virus strains.22

Obesity and Influenza

Evidence suggests obesity increases prolonged inflammatory signaling, which has a dampening effect on the antiviral immune response. Insulin resistance, which commonly co-occurs with obesity, likewise interferes with antiviral immune activity and impairs regulation of inflammatory signaling. In influenza A-infected individuals, those with obesity have prolonged viral shedding; in addition, people with obesity produce aerosols with higher concentrations of influenza virus during an infection, increasing the likelihood of transmission. Obesity has been found to increase the risk of severe influenza and infection-related complications and deaths, and influenza vaccines are less effective in those with obesity than those with normal body weight.23,24

Vaping and Influenza: A Potentially Dangerous Combination

Smoking has long been recognized as a risk factor for influenza-related pneumonia and hospitalization, and is associated with reduced effectiveness of flu vaccination.21,25 The use of e-cigarettes or vaping was recently linked to an outbreak of acute lung injury. E-cigarette or vaping product use-associated lung injury, or EVALI, is often severe and sometimes fatal even in young adults. The exact nature of the lung injury is still unclear, but an array of components of e-cigarette aerosols are being considered as possible triggers, including nicotine compounds, propylene glycol, glycerol, vitamin E acetate, lead, and arsenic.26,27 In addition to causing direct tissue damage, animal research suggests vaping impairs the immune response to respiratory infection.28 This could increase susceptibility to lung infections including influenza pneumonia. Indeed, influenza pneumonia and other lung infections have been reported to occur in those with EVALI.26,27,29 The co-occurrence of EVALI and influenza A infection appears to be especially dangerous: in one case report, rapid deterioration and death was described.30 More efforts to educate young people about EVALI could help prevent related influenza illnesses and deaths.

5 Symptoms

Influenza is typically marked by sudden acute respiratory symptoms (eg, runny nose, sore throat, and cough) as well as systemic symptoms (eg, fever, chills, malaise, muscle pain, headache, and appetite loss), but a wide range of symptoms are possible.2,16 These symptoms usually improve over two to five days and most people fully recover within seven to 10 days.1,2

Influenza symptoms are usually distinguishable from those of the common cold by their sudden onset and intensity. Even severe influenza complications can appear as early as 48 hours after symptom onset.1

Table 1: Comparison of Characteristics: Common Cold and Influenza31-36

Common Cold


Causative virus(es)

Rhinoviruses, influenza viruses, and others

Influenza A virus
Influenza B virus
Influenza C virus

Site of infection

Upper respiratory tract

Upper and lower respiratory tracts

Incubation period

1–3 days

1–4 days

Onset of illness



Duration of illness

Typically 7–10 days

Typically 7–10 days

Contagious Period

Typically 7–14 days

As early as 12 hours after exposure, typically lasting 5‒10 days

Severity of illness


Mild to severe


Nasal congestion and runny nose



Sore throat




Characteristic, usually mild to moderate

Characteristic, can be severe


Common, usually mild



Rare, low-grade

Characteristic, can be high

Muscle aches

Uncommon, usually mild

Characteristic, often severe


Common, usually mild

Characteristic, often severe

Shortness of breath



Diarrhea and/or vomiting



6 The Course of Influeza

Influenza Spread

Influenza viruses spread from person to person via inhalation of virus-harboring droplets or aerosols, and through direct contact37:

  • Droplets. Influenza viruses can spread in respiratory droplets emitted by an infected person during coughing, sneezing, singing, or talking. These droplets travel short distances (about six feet) and spread infection when they are inhaled by others in close proximity or by contaminating surfaces and contributing to contact spread.2,37
  • Aerosols. Exhaled influenza viruses can become suspended in aerosols—tiny droplets of moisture that can linger in the air for long periods of time and may be naturally carried distances as far as 12 feet. Aerosolized influenza viruses can be generated during coughing and sneezing, as well as through normal breathing.37
  • Contact. Hands that come in contact with the skin of an infected person or a contaminated surface can transmit influenza virus through touching the nose, eyes, or mouth. Influenza A virus may survive for 24–48 hours on metal and plastic surfaces and less than 8–12 hours on cloth and paper.

The extent of influenza spread, as well as its severity, is determined in part by factors such as degree of pre-existing immunity in the population and inherent virulence of the virus in circulation. During a typical outbreak of influenza, about 5–10% of adults and 20–30% of children are likely to become infected, but during pandemics, the infection rate may be higher than 50%.14,38 The transmissibility of influenza viruses is also affected by environmental factors including humidity and temperature. Winters, marked by low humidity and low temperatures, favor influenza virus spread, and flu season coincides with winter in temperate regions of the Northern and Southern Hemispheres.4 Unlike in temperate regions, influenza patterns can vary in tropical regions and remain active throughout the year. Outbreaks related to air and cruise ship travel in non-winter months have been documented.14

Infection, Incubation, and Contagious Period

When an influenza virus makes contact with a respiratory epithelial cell, such as those lining the nose or mouth, it binds to specific receptors on the cell surface. This can trigger a process by which the virus gains entry into the cell and releases its genetic material. The cell is in this way co-opted into generating proteins needed for viral replication. Infected cells produce large amounts of virus that are shed into respiratory secretions, facilitating infection spread. In addition, they release signaling molecules that activate all types of immune cells and initiate the antiviral immune response.2,16,39

The time between initial infection and symptomatic illness, known as the incubation period, is typically one to four days, but viral shedding may begin as early as 12 hours after influenza virus exposure.2 Studies indicate viral replication and shedding likely peak about 48 hours after exposure, last for five to 10 days, and correlate with severity of illness.1,2 In particular, longer duration of viral shedding has been observed in children, older adults, those with chronic disease, obese individuals, and those with compromised immune function.2

Illness and Recovery

The way influenza infection manifests in the body is largely determined by interactions between the virus and the immune system. These interactions are shaped by cytokines, signaling molecules released by infected cells and activated immune cells that regulate the antiviral and inflammatory immune response. A balanced immune response efficiently clears the virus but, in the process, causes the symptoms of the flu; an unbalanced immune response, however, can be the cause of severe illness and dangerous complications.22,39 For example, excessive cytokine signaling, such as a cytokine storm, may successfully clear the virus, but causes a hyper-inflammatory response that results in tissue damage in the lungs and sometimes other body systems.22,39,40 This is the main cause of death in influenza patients.22 Conversely, if the antiviral response is insufficient for clearing the infection, there may be few typical symptoms, but the uncontrolled infection can lead to lung damage and render one vulnerable to secondary lung infection.22,39

For most people, the immune system effectively clears infection and symptoms abate within one to two weeks. In addition, specialized immune memory cells form that can respond immediately to control a second infection by the same virus. Some of these immune memory cells can recognize multiple influenza virus strains that share certain surface proteins. This kind of cross-recognition can facilitate a more timely and effective immune response and help limit symptom severity when similar influenza viruses are encountered in the future.22,41

Inflammasomes and Cytokines in Influenza

Cytokines are intercellular messenger chemicals that regulate and shape the immune response. Some cytokines promote inflammation and accelerate the immune response, some inhibit inflammation and prevent tissue damage, and some do both. Interferons, interleukins, and tumor necrosis factor-alpha (TNF-α) are among the important cytokines that regulate the immune response to influenza infection.22,42

Inflammasomes are multi-protein structures found in immune and epithelial cells that, when activated, trigger the release of pro-inflammatory cytokines.42 When an inflammasome detects the presence of influenza virus, for example, it induces the release of cytokines that recruit immune cells, such as neutrophils, natural killer (NK) cells, and monocytes, needed to contain and eradicate the virus.43 The cascade of inflammatory signaling also leads to increased vascular dilation and permeability, as well as blood clotting.44

Overactivation of inflammasomes is thought to be an underlying factor in the massive overproduction of pro-inflammatory cytokines known as a “cytokine storm.”43 It has been proposed that conditions such as obesity and metabolic imbalances may prime inflammasomes and increase the likelihood of their overactivation. Cytokine storm, which is characterized by uncontrolled inflammatory signaling, neutrophil recruitment, free radical production, and tissue damage in the airways and sometimes throughout the body, is associated with rapid deterioration and poor outcomes in patients with viral infections such as influenza.43,45 It also increases the risk of vascular problems and blood clots, and is a primary factor contributing to outcomes such as pulmonary embolism, heart attack, and stroke.46


The most common complication of influenza is pneumonia, which can be caused by the influenza virus and/or a secondary bacterial infection. Influenza-related pneumonia, especially when it involves bacterial infection, is a leading cause of influenza-related hospitalizations and death.47 Individuals who are especially vulnerable may experience other dangerous complications including widespread viral or secondary bacterial infection, severe systemic inflammation, and multi-organ failure.21

The flu can also lead to complications involving the muscles, heart, and nervous system, though these are less common than respiratory complications.2,21 One study that included more than 80,000 hospitalized patients with influenza infection found 11.7% had an acute cardiovascular event such as heart failure or heart attack associated with their hospitalization.48 Another study that included 364 heart attack patients found the risk of heart attack was six times higher during the week after a flu diagnosis than during a period extending one year before and one year after having the flu.49 Risk factors for cardiac complications include being an older age, tobacco use, and having diabetes or cardiovascular or kidney disease. Observational research has correlated influenza vaccination with cardiovascular protection in people aged 65 years and older, further indicating the importance of vaccination for this high-risk population.50

7 Diagnosis

What Tests Are Available

Influenza virus tests used to diagnose acute illness can detect either viral proteins (antigens) or virus-specific genetic material (RNA or nucleic acids) in specimens collected from the upper or lower airways. Cultures, which have 1‒10-day turnaround times, may be helpful for public health purposes but are too slow to be clinically useful. The accuracy of diagnostic testing depends not only on the method but also on factors such as time between onset of illness and specimen collection, and specimen source, quality, handling, and processing.6 Ultimately, the test used depends on both test availability and how soon results are needed.

The Infectious Diseases Society of America recommends rapid molecular assays in outpatient settings and reverse transcription polymerase chain reaction (RT-PCR) and other molecular assays in hospital settings.6

Table 2: Influenza A and B Virus Testing Methods51



Based on

Source of Specimen

Test Time

Rapid Influenza Molecular Assays

A and B

Viral genetic material

Nasal or nasopharyngeal swab

15–30 minutes

Reverse Transcription Polymerase Chain Reaction (RT-PCR) and other molecular assays

A and B; some tests distinguish between influenza A virus subtypes; some tests distinguish between influenza virus and other respiratory pathogens

Viral genetic material

Throat or nasopharyngeal swab; nasopharyngeal or bronchial wash; nasal or endotracheal aspirate; sputum

1–8 hours, depending on the exact test

Rapid Influenza Diagnostic Tests

A and B

Viral protein

Nasal or nasopharyngeal swab, aspirate, or wash; throat swab

< 15 minutes

Immunofluorescence, direct or indirect

A and B

Viral protein

Nasopharyngeal swab or wash; bronchial wash; nasal or endotracheal aspirate

1–4 hours

Who Should Be Tested?

During the flu season, people who do not require hospitalization and are not at high risk of complications can be diagnosed with influenza based on their symptoms. Influenza virus testing is only recommended if the test result will affect treatment decisions (such as whether to administer antibiotics) or guide infection control strategies (such as for nursing home residents). Diagnostic testing for influenza is therefore recommended in52:

  • Immunocompromised patients, both hospitalized and not hospitalized, with symptoms of acute respiratory illness
  • Patients hospitalized for acute respiratory illness
  • Those who develop acute respiratory illness while hospitalized for another reason
  • Those hospitalized for exacerbations of chronic obstructive pulmonary disease, asthma, coronary artery disease, or congestive heart failure, since influenza can worsen these conditions

In addition, outside of the flu season, healthcare providers may consider influenza virus testing for hospitalized and non-hospitalized patients who exhibit symptoms of acute respiratory illness, including fever, especially if they have a high risk of complications or have been traveling in regions where influenza activity is unknown.52

8 Prevention

Strategies for reducing the risk of influenza and its complications include basic personal precautions and influenza vaccination.


Basic precautions for limiting the spread of influenza include53:

  • Staying home when sick
  • Keeping a distance from others who may be sick
  • Covering your mouth and nose with a tissue (or the inner elbow) when coughing or sneezing
  • Minimizing touching of eyes, nose, and mouth with unwashed hands
  • Practicing good hand hygiene
  • Cleaning high-touch surfaces frequently
  • Using face masks when unable to avoid close contact if you or others may be sick.

Hand hygiene. Influenza viruses on skin are inactivated by washing with soap or using alcohol-based hand rubs.54 Frequent hand washing and sanitizing have been correlated with reduced spread of influenza and other viruses.55 Although the effectiveness of hand hygiene is more difficult to assess in the community, its value in healthcare settings has been well established.56 Washing hands at least three and possibly five or more times per day may be needed to substantially reduce infection risk.57-59 Effective hand washing requires rubbing soapy hands together for at least 20 seconds, then rinsing and completely drying hands. When a sink is not available, hand sanitizers with alcohol concentrations of 60% or higher are recommended for their broad antimicrobial effects and should be rubbed into hands until completely dry for best results.60

Face masks. Medical (surgical) face masks are designed to reduce the spread of respiratory viruses by droplet, while N95 respirator masks can also reduce viral spread by aerosol. Both appear to help reduce viral respiratory infections, including influenza. Observational studies indicate wearing a medical or respirator mask is correlated with substantially reduced risks of influenza and other viral respiratory infections, and the relationship may be stronger in healthcare settings than in community settings.61 Although findings from community-based studies have been mixed, the following factors seem to increase the likelihood that masks will be effective in preventing influenza spread62:

  • High mask-use compliance
  • Use of masks by close contacts before or soon after the appearance of symptoms
  • Mask use in combination with hand hygiene measures

Importantly, face masks may be more beneficial for reducing community spread of viral infections during pandemic times, when compliance may be better and a positive impact more likely. The effectiveness of reusable cloth masks has not been well studied, but factors such as proper composition, fit, handling, and cleaning are likely to determine their usefulness.

Gargling and nasal irrigation. Regular gargling and the use of nasal irrigation and sprays may reduce the risk of influenza and other respiratory infections.63 Gargling with an iodine solution or salt water have both been found to reduce respiratory infections in preliminary studies.64,65 In a controlled clinical trial with 387 participants, gargling at least three times per day was found to lower the risk of upper respiratory tract infections and gargling with plain water was more effective than an iodine-based solution. The trial also noted that participants who gargled but got sick were less likely to develop lower respiratory symptoms.66 Gargling with green tea may also have a preventive effect against influenza infection.67

Clinical trials have found saline nasal sprays and drops reduced symptoms in children with upper respiratory infections. In controlled trials in adults, daily use of saline nasal spray reduced the incidence of upper respiratory infections,68 and saline nasal irrigation reduced shedding of influenza A and other respiratory viruses, household transmission, use of over-the-counter medications, and duration of illness in patients with symptoms of respiratory infections.69


Annual vaccination against seasonal flu is an important public health strategy for limiting the scope of outbreaks and epidemics and is recommended for everyone six months of age and older who does not have contraindications.70,71 There are several types of influenza virus vaccines available4:

  • Inactivated influenza vaccines. These vaccines contain viral proteins from a combination of two kinds of influenza A and either one or two kinds of influenza B.
  • Recombinant influenza vaccines. These vaccines also contain viral proteins but are produced using non-influenza viruses that have been genetically altered to produce the desired proteins.
  • Live attenuated influenza vaccine. These vaccines contain influenza A and B viruses that have been weakened through genetic manipulation.

The specific viruses used in manufacturing new vaccines each year are selected based on year-round surveillance of circulating viruses, extent to which the viruses are spreading, and effectiveness of the previous season’s vaccine against those viruses. The goal of vaccination is to elicit a minor immune response that results in sufficient immune memory to improve responsiveness should exposure to circulating viruses occur.4,70

The choice of vaccine depends partly on the age and health status of the individual. Live attenuated influenza vaccines may be preferred for children since they are administered intranasally.4,71 In vulnerable populations, such as those under 2 years old, the elderly, pregnant women, those with chronic illnesses, and those with weak immune function, live attenuated vaccines are not recommended.71 High-dose inactivated influenza vaccines or vaccines containing adjuvants (non-viral compounds that enhance the immune response to the vaccine) may be recommended in older individuals who have a weaker response to vaccination generally. Although inactivated influenza vaccines are commonly produced using viruses grown in an egg medium, cell-based vaccines are available for those with egg allergy.4

The effectiveness of the seasonal influenza vaccine varies from year to year depending in part on how well the circulating viruses match those used to develop the vaccine, and how much antigenic drift (small mutations in virus genetic code) occurs. Estimates from meta-analyses indicate that, when the influenza viruses in available vaccines are a good match with those in circulation, vaccination may reduce the risk of influenza infection by 40–60%.72 In addition, vaccination may reduce the risk of severe illness, adverse cardiovascular and respiratory outcomes, and death due to any cause, particularly in the elderly and those with chronic diseases.7,8

Influenza Vaccination and Cardiovascular Protection

Heart attack and stroke are more common during and in the days following influenza-like illness, and some reports indicate lower rates of these events in vaccinated individuals.73 Observational studies and clinical trials suggest influenza vaccination may lower risks of major cardiovascular events and cardiovascular and all-cause mortality in those with heart disease or diabetes.74,75 Furthermore, meta-analyses of data from randomized controlled trials indicate influenza vaccination is likely to substantially reduce the risk of major cardiovascular events in patients with high cardiovascular risk, and the effect may be stronger in those with more severe heart disease.76-78

Findings from a three-year randomized controlled trial with 5,260 participants indicate annual vaccination with high-dose and regular dose influenza vaccines can have similar protective effects.79 However, observational evidence from a 15-year study in 43,000 older individuals suggests the adjuvanted influenza vaccine may be more effective than the non-adjuvanted vaccine for reducing hospitalizations due to pneumonia, cardiac events, or stroke.80

The protective benefit of the seasonal influenza vaccine diminishes quickly relative to other types of vaccines, and it has been reported to be suboptimal after four months. This is long enough to encompass a typical flu season but may leave world travelers unprotected the rest of the year.72

Inactivated influenza vaccines commonly cause temporary mild soreness at the injection site, as well as irritability, fever, malaise, muscle pain, and other systemic symptoms lasting several days in children. Live attenuated influenza vaccine can cause mild symptoms of influenza illness such as nasal congestion, sore throat, and cough, as well as systemic symptoms such as fever and decreased appetite. Rarely, serious unexpected adverse side effects have been associated with influenza vaccination.81 The most common serious adverse reaction to influenza vaccines is anaphylaxis (a life-threatening allergic reaction), which is estimated to occur at a rate of 1.6 cases per million doses of standard trivalent influenza vaccine administered.82 Another possible serious adverse reaction is Guillain-Barré syndrome (GBS), an autoimmune disorder affecting the nerves. An association between influenza vaccination and a small increase in risk of GBS was detected in 1976. It was estimated the occurrence of GBS increased by one case per 100,000 vaccinations administered. Since then, the risk of GBS possibly related to influenza vaccine varies from year to year but is generally 1‒2 cases per million vaccinations. It is important to note that studies suggest it is more likely for a person to get GBS after they have the flu than after the vaccine.83

Immune Senescence, Influenza, and Vaccination

Aging is naturally marked by a progressive decline in biological functions. This process takes its toll on immune homeostasis, triggering the changes in immune signaling and activity known as immune senescence. Immune senescence is marked by reduced infection defenses and increasingly dysregulated inflammation. As a result, older people have more difficulty controlling infections like influenza, and chronic low-level inflammation increases their susceptibility to influenza-related pneumonia and acute respiratory distress syndrome (ARDS), as well as complications involving the heart, muscles, nerves, liver, and kidneys.11 Vaccination, which also requires a competent immune response, is notably less effective in those with immune senescence.12 In fact, despite a >60% influenza vaccination rate among those over 65 years in the United States, this age group accounts for approximately two-thirds of influenza hospitalizations and 90% of influenza deaths each year.10

New influenza vaccines are being developed to overcome some of the age-related problems in vaccine responsiveness. Vaccines with four-fold higher doses of antigens (the proteins that elicit an immune response) have been found to induce a more robust antibody response and reduce the risk of influenza, hospitalization, and pneumonia compared with standard dose vaccines in the elderly.84 The addition of an adjuvant known as MF59 (a derivative of squalene), an oil-in-water emulsion, may enhance the immune response to vaccination in the elderly.84,85

Another strategy that may improve vaccine responsiveness in older people is administering the vaccine under the skin rather than into muscles. The dermal skin layer is rich in immune cells and intradermal influenza vaccines have been found in some studies to induce a more robust antibody response in older subjects. However, whether or not this translates into lower incidence and severity of influenza illness is still unknown.84 An intradermal influenza vaccine was approved for use in the United States in 2011 but was later discontinued due to low demand.70

9 Treatment

Influenza is usually a mild self-limited infection in people who are otherwise healthy and does not require treatment with antiviral medications.1 Importantly, antibiotics are not appropriate in the treatment of uncomplicated influenza and should be reserved for those with secondary bacterial infections.9 Some over-the-counter cold medicines may reduce symptoms and provide comfort. However, parents should bear in mind aspirin and aspirin-containing products should be avoided in children due to the possibility of Reye’s syndrome, a rare and potentially fatal condition associated with aspirin use, in this age group.86

Antiviral drugs are recommended in influenza patients with rapidly progressing infection or a high risk of complications, as well as those who are hospitalized. In these patients, antiviral drug therapy may reduce the severity and risk of complications and decrease mortality.9 Antiviral drugs are also used to prevent and treat influenza during outbreaks in hospitals, nursing homes, and other healthcare settings.1 Individuals with influenza who are healthcare workers and likely to come in contact with high-risk individuals may also be treated with antiviral therapy.9

In otherwise healthy individuals with influenza, antiviral therapy is generally unnecessary; however, the initiation of antiviral therapy within 48 hours of symptom onset may shorten the duration of illness by about one day.9

There are several antiviral drugs for influenza1,9:

  • Neuraminidase inhibitors. Oseltamivir (Tamiflu), zanamivir (Relenza), and peramivir (Rapivab) are neuraminidase inhibitors. These drugs interfere with the release of viruses from infected cells. Oseltamivir is an oral drug, zanamivir is inhaled, and peramivir is used intravenously.
  • Endonuclease inhibitor. Baloxavir marboxil (Xofluza) is an endonuclease inhibitor and disrupts viral replication. This drug is available as an oral medication.
  • Adamantanes. Amantadine (Symmetrel) and rimantadine (Flumadine) belong to a class of antiviral drugs called adamantanes and are only effective against influenza A virus.

Viruses can quickly develop resistance to antiviral drugs. Influenza viruses circulating in the United States currently show little resistance to neuraminidase inhibitors and baloxavir marboxil, but resistant strains can emerge at any time, including during treatment.1,87 Widespread resistance to adamantanes has been observed among influenza A viruses circulating in recent years in North America and Asia, and current recommendations advise against their use for influenza treatment or prevention at this time.1,9 The use of oseltamivir is limited by its association with adverse side effects such as skin reactions, nausea and vomiting, psychiatric symptoms, and kidney problems.1,88 Skin reactions and diarrhea have also been associated with the use of peramivir and baloxavir marboxil, and zanamivir can cause respiratory problems in those with asthma or chronic obstructive pulmonary disease (COPD).9

10 Novel and Emerging Therapies

Repurposed Drugs

Drug repurposing is the process of identifying new conditions for which known medications can be used beneficially. Repurposing is faster, less expensive, and often safer than new drug development. The prospect of repurposing drugs to treat influenza is especially appealing since currently available treatment options are not highly effective.89

Nitazoxanide. Nitazoxanide (Alinia) is a drug used to treat intestinal parasites. It has demonstrated antiviral activity against influenza A and B viruses in the laboratory90 and early clinical trials in humans suggest it may reduce viral load and symptoms of infection. However, not all clinical trials have shown benefit.91 More clinical trials are needed to determine whether nitazoxanide or similar compounds may be effective for influenza infection.

Statins. Statins are medications used to lower high cholesterol levels. Statins have also been found to have general anti-inflammatory and immune-modulating effects that may be beneficial in patients with influenza. Some, but not all, observational studies have noted a lower mortality rate among hospitalized patients with influenza who were incidentally taking statins.89 A randomized controlled trial found that atorvastatin (Lipitor) led to greater symptomatic improvement at 72 hours than placebo among 116 subjects with influenza. However, this endpoint was a secondary outcome and the study’s primary endpoint of change in inflammatory markers did not reach statistical significance.92

Anti-diabetes drugs. Anti-diabetes drugs targeting the repair of metabolic disturbances have been found to have immune-modulating effects such as reducing inflammatory cytokine signaling and regulating antibody activity. These effects may make them useful in treating viral infections, including influenza. In newly diagnosed type 2 diabetes patients, treatment with the anti-diabetes drug metformin (Glucophage) was found to improve the function of antibody-producing immune cells as well as the antibody response to influenza vaccine.93 Other research, however, has found diabetics using metformin have a suppressed immune response to influenza vaccination.94,95 Pioglitazone (Actos), an anti-diabetes drug in the peroxisome proliferator-activated receptor (PPAR) agonist class, has also demonstrated promising anti-inflammatory and anti-influenza effects in preclinical research.96

Cimetidine. Cimetidine(Tagamet) is an over-the-counter drug that reduces gastric acid secretion by inhibiting a type of histamine receptor (H2 receptors) found in the gastric lining. It is mainly used to treat gastroesophageal reflux disorder (GERD), but is sometimes used to treat gastric and duodenal ulcers and viral warts.97 H2 histamine receptors are also found on all types of immune cells, and cimetidine has been shown to modulate immune cell activity. Preclinical studies indicate cimetidine can enhance antiviral immune function while diminishing the inflammatory immune response.98 Note: cimetidine can interact with many drugs and potentially cause adverse effects. Talk with a qualified healthcare provider or pharmacist before starting cimetidine to be sure you do not take any drugs that could interact with cimetidine.

Antiviral Drugs

Development of new antiviral drugs that target aspects of viral entry and replication, as well as enhancement of host defenses, is a subject of intense research attention. Favipiravir (Fabiflu, Avigan) and fludase are among the more promising new therapeutics under investigation.99,100

Favipiravir. Favipiravir, an antiviral drug used to treat influenza, works by interfering with viral replication in infected cells. It has demonstrated antiviral activity in the laboratory against all subtypes of influenza viruses, including those that have low or no sensitivity to other antiviral drugs, as well as a range of other viruses such as Ebola, Lassa fever, Marburg, Nipah, and Zika viruses.100-102 In addition to having a broad spectrum of activity, favipiravir appears not to induce resistance, and may be effective even when started 72 hours after infection. Favipiravir is not approved for use in the United States, but is approved to treat influenza in Japan.100,101 Importantly, favipiravir is contraindicated in pregnancy due to possible teratogenic effects, and its safety in children is still in question.100,103

Fludase. Fludase is a drug with a host-based mechanism of action: rather than targeting viruses, it targets respiratory mucosal cells, reducing expression of receptors used by viruses to gain entry. Early-stage clinical research suggests it may be active against a broad array of influenza virus strains, and may safely reduce viral load and shedding in infected individuals.


Another approach to treating influenza is through the therapeutic use of antibodies. Studies have identified antibodies that have broad activity against influenza A virus strains. In animal research, the use of cloned antibodies, alone and in combination with antiviral drugs, has been shown to reduce viral spread and severity of illness.104 Several monoclonal antibody drugs have reached phase II clinical trials in humans and have been found to reduce viral shedding and clinical symptoms after experimental exposure to influenza A virus.100,104 However, antibody therapy has not yet been found to have clear advantages over oseltamivir.100

Convalescent plasma. Convalescent plasma is obtained from donors who have recently recovered from viral illness and is rich in antibodies that support specific antiviral defense. Convalescent plasma has been used for decades in the treatment of severe respiratory viral illnesses, including influenza.105,106 Multiple studies have reported benefits from convalescent plasma therapy in patients infected with various strains of influenza A virus, particularly when started early: lower mortality, shorter hospital stays, and less need for intensive care and emergency interventions have been noted, and there have been no reports of serious adverse effects.105 However, recent randomized controlled trials and meta-analyses have not clearly demonstrated the effectiveness of convalescent plasma therapy in influenza patients.106 One recent randomized controlled trial in 308 influenza A and B patients found the addition of convalescent plasma to standard antiviral therapy was only beneficial in those with influenza B infections.107


Interferons (IFNs) are cytokines that are critical to initiating and sustaining antiviral immune activity. Preclinical studies suggest interferon-lambda (IFN-λ, also called type III IFN) is a critical early player in clearing influenza virus, limiting viral transmission, and producing lasting antiviral protection.108 It also appears to trigger less pro-inflammatory signaling than later-acting IFN-α and IFN-β (type I IFNs).109 Animal research indicates early treatment of influenza with therapeutic pegylated-IFN-λ may result in better control of viral replication, less lung tissue damage, and more rapid recovery.109,110 One study in mice, however, found IFN-λ therapy during influenza infection impaired the immune response to bacteria, raising concern that this treatment may increase the risk of secondary bacterial infection.111 Clinical trials in humans with the flu have not yet been undertaken, but, subcutaneous injections of IFN-λ have shown promising results in patients with another respiratory viral infection.

Universal Vaccines

Although they are currently the most effective medical tool for preventing influenza and its complications, seasonal influenza vaccines provide limited protection and require annual modification based on changes in circulating viruses. Ongoing research is focused on developing a universal influenza vaccine that would be effective against all influenza types and subtypes that infect humans regardless of antigenic drift and shift and would not need modification each year.112 One systematic review identified 69 clinical trials using 27 novel influenza vaccines conducted between January 2010 and December 2019. These investigational vaccines differ in the viral proteins (antigens) they incorporate or mimic to induce an immune response, mechanism or medium for antigen delivery, and use of adjuvants to enhance the immune response. One of these vaccines demonstrated promising effects in phase III testing in children; two others are currently undergoing phase III clinical trials.113

11 Diet and Lifestyle Interventions

Poor nutritional status, whether from undernutrition or overnutrition, has been recognized for centuries as a factor linked to severe influenza and complications.114 A healthy diet that supplies adequate amounts of vitamins A, B complex, C, D, and E, as well as zinc, selenium, magnesium, iron, copper, and omega-3 fatty acids supports normal immune function and defense against influenza and other viral respiratory infections.115,116 Dietary fiber has been found to improve antiviral immune activity while mitigating the inflammatory response,117 and flavonoids from plant foods may have specific antiviral effects and may help reduce tissue-damaging oxidative stress and inflammation during the response to infection.118 Fermented foods that supply probiotic strains may also help by supporting a balanced immune response to influenza infection.119

Likewise, a sedentary lifestyle may contribute to increased severity of influenza and risk of complications. A meta-analysis of 14 randomized controlled trials found regular moderate aerobic exercise, such as walking and cycling, may reduce the severity of acute respiratory illnesses, though it does not appear to affect their incidence.120 Moderate exercise enhances immune defenses while lowering systemic inflammation, and has been found to mitigate the effect of aging on immune function.121 Exercise may also improve the immune response to the influenza vaccine in older individuals.122

Sleep is important for balanced immune function and clinical evidence suggests chronic sleep disturbance may contribute to poor influenza vaccine response and increased risk of acute respiratory illness.123,124 During an infection, immune activation can promote increased sleep duration and intensity, which may in turn assist in recovery.124

Chronic psychological stress is another factor that interferes with normal immune defenses and raises inflammatory signaling, increasing the risk of respiratory infections. High levels of perceived stress can weaken the response to influenza vaccination and may increase vulnerability to influenza infection.125-128

12 Nutrients

Probiotics, Prebiotics, and Synbiotics

Beneficial microbes that colonize the intestines are integral to healthy immune function. Even in the respiratory tract, the gut microbiome helps regulate antiviral and inflammatory immune responses against viral infections including influenza. An upset in the intestinal microbial balance (dysbiosis) is associated with chronic inflammatory conditions of the airways, including allergies, asthma, and COPD, and may increase the risk of viral respiratory infections. Probiotic supplements, especially those with species of Lactobacillus and Bifidobacterium, have been found to reduce the incidence and severity of upper respiratory viral infections, including the flu.129

Probiotics and influenza prevention. Multiple clinical trials show probiotics can reduce the risk of respiratory infections, including colds and influenza-like illnesses, but few have looked at their effects on laboratory confirmed influenza. In a placebo-controlled trial that included 96 elderly nursing home residents, eating 100 grams of yogurt fortified with L. delbrueckii ssp. bulgaricus daily for 12 weeks led to increased salivary anti-influenza antibody activity.130 However, this same probiotic yogurt did not lower the risk of influenza infection in a 16-week placebo-controlled trial in 961 female healthcare workers.131 In a trial that included 196 elderly nursing home residents, laboratory confirmed viral respiratory infections (some of which were influenza) occurred in 15% of those given 20 billion colony forming units (CFUs) ofL. rhamnosus GG daily and 22.9% of those given placebo.132 An open trial that included 1,089 children also reported promising findings: in those receiving a probiotic strain of L. brevis, at a dose of 6 billion CFUs five days per week for eight weeks, 15.7% were diagnosed with influenza by a physician; in those not receiving the probiotic, 23.9% were diagnosed with influenza.133

Probiotics and influenza-like illness. In one trial that included 136 participants with a history of frequent episodes of common colds and influenza-like illnesses, taking a daily supplement containing at least 63 million CFUs of L. paracasei, L. casei, and L. fermentum reduced the frequency of flu-like symptoms and upper respiratory infections compared with placebo. The probiotic combination also increased levels of IFN-γ, a cytokine that activates antiviral immune activity, and gut secretory immunoglobulin-A, an antibody that plays a critical defensive role against infections.134 A six-week placebo-controlled trial in 581 stressed college students found those taking a daily B. bifidum supplement had more healthy days and fewer episodes of cold or flu symptoms lasting one day or longer.135 In a meta-analysis that included data from 11 randomized controlled trials with a total of 2,417 children, probiotic use was found to decrease the risk of both upper and lower respiratory infections.136

Synbiotics, which contain both probiotic organisms and prebiotic saccharides, have also been shown to reduce respiratory infection risk. A series of three trials in a combined total of 721 healthy participants compared the effects of four synbiotic preparations made with mixed strains of L. plantarum (LP 01 and LP 02), L. rhamnosus (LR 04 and LR 05), and B. lactis (BL 01), along with a prebiotic (either fructooligosaccharides [FOS] or galactooligosaccharides [GOS]), to placebo during three flu seasons. All of the preparations were found to reduce the incidence, severity, and duration of flu-like illnesses, as well as upper respiratory infections generally.137 A meta-analysis that included findings from 16 randomized controlled trials with a combined total of more than 10,000 participants found supplementing with synbiotics reduced the incidence of all respiratory tract infections by 16%.138

Probiotics and influenza vaccine response. Since certain probiotics appear to improve the immune response to influenza viruses, investigators have examined their ability to affect the response to influenza vaccination. In a placebo-controlled trial in 98 elderly subjects living in nursing homes, taking a supplement providing 3 billion CFUs per day of L. coryniformis for two weeks strengthened the response to influenza vaccination and reduced the incidence of respiratory infection symptoms and influenza-like illness during five months of monitoring.139 A meta-analysis of 12 randomized controlled trials with a combined total of 688 participants found both probiotic and prebiotic supplements increased antibody responsiveness to influenza vaccination. In the seven probiotic trials, single probiotic strains were used, including strains of L. paracasei, L. casei, L. rhamnosus, and B. longum. The five prebiotic trials used FOS, GOS, and/or inulin.140 Findings from a randomized controlled trial in which elderly participants were given a heat-treated probiotic supplement or placebo prior to influenza vaccination suggest those aged 85 years and older may benefit most from this type of intervention.141


Beta-glucans (eg, beta 1,3/1,6 glucan) are a common type of prebiotic fiber, indigestible by human enzymes but fermentable via the digestive action of beneficial gut bacteria. They are found in foods such as whole grains and mushrooms, as well as yeasts and algae.142,143 Beta-glucans have been found to stimulate antimicrobial defenses through direct action on intestinal immune cells and modulate inflammation through their ability to improve the health of the gut microbiome.143-145 Findings from animal research suggest supplementation with beta-glucans may improve the immune response to influenza vaccination and enhance recovery from influenza infection.146,147

In a study of 52 healthy adults, ingestion of 5 or 10 grams of shiitake mushrooms daily for four weeks resulted in increased levels of immune cells with the ability to proliferate. Additionally, levels of secretory immunoglobulin A in the saliva were increased, which implies improved gut immunity. The authors of this study attributed the beneficial effects of the mushrooms to compounds found in shiitake mushrooms, including beta-glucans and other compounds (eg, ergothioneine, linoleic acid).148

In a placebo-controlled trial in 357 marathon runners, those given a yeast extract providing 250 mg beta-glucans daily for 45 days before, the day of, and 45 days after running a marathon had fewer days with upper respiratory symptoms, reduced symptom severity, and fewer workout days missed after the marathon than those given placebo.149 A similar placebo-controlled trial included 182 runners and found supplementing with 250 mg of yeast-derived beta-glucans per day for 28 days after running a marathon decreased the number of post-marathon days with cold or flu symptoms by 37%. The same publication reported findings from a separate placebo-controlled trial in 60 athletes indicating supplementation with beta-glucans for 10 days before intense exercise mitigated exercise-induced immune suppression.150

In 175 children with recurrent respiratory infections, those given supplements containing beta-glucan extracted from mushrooms (dosed according to body weight) had fewer flu-like illnesses and respiratory infections during 12 months of monitoring than those given placebo.151 Additionally, several randomized controlled trials have shown beta-glucans can help reduce the incidence and severity of common cold symptoms.152-155

Saccharomyces cerevisiae

Saccharomyces cerevisiae (S. cerevisiae) is a probiotic yeast that is consumed in fermented foods such as beer and sourdough bread. It has been hypothesized that S. cerevisiae and other probiotic yeasts may enhance the immune system by improving the physical barrier of the gastrointestinal system and helping regulate cytokine secretion.156

A yeast fermentation product partially derived from S. cerevisiae (EpiCor) has been shown to protect against cold and flu-like symptoms in two clinical trials. In a randomized controlled trial of 116 participants who had not received a recent seasonal influenza vaccine, 500 mg EpiCor daily significantly reduced the incidence of common cold or flu-like symptoms compared with placebo. When symptoms were measured individually, EpiCor significantly reduced 10 of 11 symptoms, with no effect on weakness. Although the duration of symptoms was numerically reduced from 4.25 to 3.59 symptom days with EpiCor, there was no significant difference in duration in this study.157 When EpiCor was evaluated in 116 individuals recently vaccinated against influenza, similar results were reported: EpiCor significantly reduced the incidence of cold or flu-like symptoms as well as duration of symptoms (from 5.01 to 4.16 days) compared with placebo.158


Several ginseng species, including Korean or red ginseng (Panax ginseng), American ginseng (Panax quinquefolius), and Chinese ginseng (Panax notoginseng), have been studied for their ability to modulate immune function and prevent and treat infections. Although not identical, these ginseng species have similar active constituents and overlap in therapeutic potential.159 Ginseng extracts have been shown to activate the antiviral immune response while reducing the inflammatory response, possibly by lowering oxidative stress, and research in animals suggests ginseng may improve outcomes in influenza infection.159,160

A meta-analysis of 10 randomized controlled trials found ginseng may reduce the risk of seasonal colds and flu. The analysis also showed ginseng has the potential to increase the effectiveness of the flu vaccine.160 In a randomized controlled trial, 43 community-dwelling adults aged 65 years and older took either 400 mg of a standardized ginseng (Panax quinquefolius) extract per day or placebo for four months. After the first four weeks, the subjects received a standard influenza vaccine. There was no difference in rates of acute respiratory symptoms between the groups during the first two months. In the next two months, 62% of those receiving the ginseng extract, compared with 32% of those receiving placebo, experienced no acute respiratory illnesses. In addition, among those who developed infections, the average duration of symptoms was 5.6 days in the ginseng group versus 12.6 days in the placebo group.161 A report on two placebo-controlled trials in elderly residents of long-term care facilities (with 89 subjects in one trial and 109 in the other) found 400 mg per day of the same ginseng extract lowered the risk of acute respiratory infections due to influenza or respiratory syncytial virus by 89% compared with placebo. About 90% of subjects in these studies had received the influenza vaccine.162

In a randomized controlled trial, 100 healthy volunteers who had not been vaccinated against influenza were given 3 grams of red ginseng per day or placebo for 12 weeks during flu season. The ginseng-treated group experienced fewer influenza-like illnesses: 24.5% versus 44.9% of those in the ginseng and placebo groups, respectively, experienced one or more influenza-like illnesses.163 Another 12-week, randomized, placebo-controlled trial examined the effect of 100 mg per day of a standardized extract of red ginseng on the incidence of influenza and common colds in 227 healthy individuals. All participants were vaccinated against the flu in week four of the study. Ginseng-treated participants had a stronger immune response to the flu vaccine and a 64% lower number of cold and flu cases than participants given placebo.164

Green Tea

Green tea (Camellia sinensis) is a rich source of polyphenols known as catechins. Green tea catechins have demonstrated antiviral action against influenza and other respiratory viruses in preclinical research.165,166 In a randomized controlled trial in 108 healthy adults, green tea capsules providing approximately the equivalent of 10 cups of green tea per day for three months reduced the risk of flu-like illnesses and common colds lasting two days or longer by 22.9% and the number of days with cold or flu symptoms by 35.6% compared with placebo. In addition, immune cells from those receiving green tea exhibited increased antiviral activity.167 In a controlled trial that included 270 healthcare workers, over 95% of whom were vaccinated against influenza, those receiving a high dose (171 mg) of green tea catechins daily for 12 weeks in the winter had a lower rate of influenza-like illness (1.2%) than those taking 57 mg of green tea catechins (5.9%) or those receiving placebo (4.7%). In addition, high-dose green tea-treated participants had fewer upper respiratory infections overall.168 Another trial that included 197 healthcare workers found taking 378 mg per day of tea catechins, along with 210 mg per day of theanine (another compound from green tea), for five months resulted in fewer influenza virus infections: 4.1% of those receiving green tea compounds and 13.1% of those receiving placebo developed influenza virus infections.169

Observational research also suggests drinking green tea may help protect against influenza. One study compared data from 179 influenza patients and 353 matched controls who did not contract influenza during a flu season, finding those who consumed five or more cups of green tea per week had a 39% lower risk of influenza than those who drank less than one cup per week.170 Another study followed 1,121 subjects through a full flu season and noted the incidence of influenza was 61% lower in those who drank green tea two or more times per week.171 A study that looked at the relationship between green tea consumption and influenza virus infections in children found children who consumed green tea six or more days per week had about 40% reduced odds of developing an infection compared with those who drank green tea three or less days per week.172

Multiple clinical trials have found the risk of influenza was reduced by regular gargling with green or black tea or tea compounds. A meta-analysis that included findings from five randomized controlled trials with a combined total of 1,890 participants found gargling with tea or tea extracts reduced the likelihood of influenza by 30%.67


Black elderberry (Sambucus nigra) has a long history of traditional use in the treatment of colds and flu. Elderberry extracts are rich in polyphenols that are potent free radical scavengers and have been found to reduce inflammatory signaling.173 In addition, elderberry extracts have demonstrated antiviral activity against influenza A and B viruses in cell culture and animal studies.174-177

In a randomized controlled trial, 60 adults who had developed influenza-like symptoms within the previous 48 hours were given elderberry syrup, 15 mL four times daily, or placebo for five days. Those treated with elderberry recovered an average of four days sooner and were less likely to use acetaminophen (Tylenol) or a nasal decongestant compared with placebo.178 In another placebo-controlled trial in 27 adults and children with viral respiratory infections, nearly 90% of those with influenza who received elderberry extract were fully recovered within three days versus six days with placebo. The elderberry extract was taken twice daily by children and four times daily by adults for only three days in this investigation.179 A review of five clinical trials concluded that elderberry extract can reduce influenza symptoms and shorten duration of illness when started within 48 hours of symptom onset.180 A meta-analysis of randomized controlled trials concluded elderberry reduced symptoms of viral respiratory infections including influenza.181 However, not all trials have had positive findings: in one randomized controlled trial that enrolled 87 adults and children seen in hospital emergency rooms for moderate-to-severe respiratory symptoms and diagnosed with influenza, treatment with elderberry extract had no effect on outcomes.182


Andrographis (Andrographis paniculata) is used in Ayurvedic and traditional Chinese herbal medicine for treating common colds and flu, sore throat, and fever. Extracts of andrographis have exhibited immune-stimulating, anti-inflammatory, antiviral, and antibacterial actions in preclinical studies.183-185 In a cellular model of influenza A H1N1 infection, andrographis was found to inhibit neuraminidase (a protein involved viral replication).186 Neuraminidase-inhibiting drugs like oseltamivir are used to treat severe influenza. Andrographis extract has been found to reduce viral load, decrease lung inflammation, and increase survival in mice infected with influenza A viruses.187,188 In 20 healthy volunteers, taking 4.2 grams per day of andrographis extract for three days increased the number of immune cells in circulation.189

One research group reported on two controlled trials, one of which had 540 and the other 66 participants. Both trials found those treated with a combination of andrographis and Siberian ginseng ( Eleutherococcus senticosus), 300 mg three times daily for 4‒5 days, had faster recovery and fewer complications from influenza.190 In addition, multiple randomized controlled trials and two meta-analyses found andrographis extract, alone and in herbal combinations, reduced symptoms of upper respiratory tract infections and may be especially helpful in alleviating cough and sore throat.183,191

Vitamin C

Vitamin C is an important immune modulator, and evidence indicates it can increase production of interferons (antiviral cytokines) during the early stages of influenza virus infection.192 As an antioxidant, vitamin C also reduces tissue-damaging oxidative stress caused by viral infection and immune cell activation. Studies have shown vitamin C levels drop during infection, and vitamin C therapy may improve the antiviral immune response, suppress pro-inflammatory cytokine signaling, decrease symptom severity, and shorten duration of illness.193,194 Vitamin C supplementation may be especially valuable in athletes since heavy physical exertion increases oxidative stress and may increase the rate of vitamin C depletion.193

In one controlled trial, 114 patients hospitalized with influenza received 300 mg vitamin C per day and 112 similar patients received no vitamin C. Two patients in the vitamin C group and 10 in the control group developed pneumonia, and the average length of hospital stay was nine days in the vitamin C group versus 12 days in the control group.195

High-dose vitamin C therapy has been found to mitigate lung damage in patients with viral pneumonia and ARDS. In critically ill patients, intravenous vitamin C is needed to achieve the high blood levels thought to be necessary to overcome infection-related oxidative stress. Promising results have been reported in cases of patients with influenza-related respiratory failure who received intravenous vitamin C as part of their treatment.194

Vitamin D

Vitamin D modulates the immune response by interacting with receptors on various types of immune cells. Its complex effects on immune activation support antiviral defenses and limit inflammation.196-198

Most observational studies in adults and children have noted an association between higher vitamin D levels and lower risk and severity of acute respiratory infections including influenza.199,200 One study monitored 198 healthy adults through the winter months in Connecticut and found those who maintained vitamin D levels ≥38 ng/mL had 2.7 times lower incidence of acute respiratory illnesses and 4.9 times fewer sick days than those whose vitamin D levels were <38 ng/mL. Of the seven cases of confirmed influenza that occurred during the study, only one was in the group with higher vitamin D levels.201

Despite evidence correlating low vitamin D status with poor influenza outcomes, randomized controlled trials have not shown conclusively that supplementation is beneficial. Differences in participant selection and dosing schedules, as well as a lack of baseline vitamin D measurement in some trials, have made it challenging to draw conclusions.197,199 One meta-analysis found that, while daily or weekly dosing of vitamin D may reduce the risk of viral respiratory infections, bolus dosing (750 mcg [30,000 IU] or more) had a negative impact. This finding highlights the complex nature of the role of vitamin D in regulating immune function and the importance of appropriate dosing.202 It has been proposed that individualized doses, not exceeding 250 mcg (10,000 IU) per day, aimed at achieving vitamin D levels of 40–60 ng/mL may be more useful for preventing influenza and other viral respiratory illnesses than standardized doses.


N-acetylcysteine (NAC), a form of the amino acid L-cysteine, is best known for its use as an antidote to acetaminophen toxicity; however, its ability to support antioxidant systems and reduce oxidative stress by raising glutathione production gives it multiple potential uses in conditions related to toxicity, infection, inflammation, stress, and aging.203,204 Preclinical research suggests NAC may have beneficial effects in influenza. For instance, NAC reduced inflammation and inhibited viral replication in influenza-infected cells from the pulmonary lining. Also, in mouse models of influenza, NAC decreased lung damage and increased survival.205,206

A randomized controlled trial that included 262 frail older adults who had not been vaccinated against influenza during the same or previous seasons found taking 1,200 mg NAC per day for six months reduced the incidence of influenza-like illness: 29% of those receiving NAC versus 51% receiving placebo developed the flu. Interestingly, viral testing revealed the infection rate was similar in both groups, but most of those treated with NAC remained asymptomatic. In addition, severity of influenza symptoms was lower in the NAC group.207 Clinical research has shown NAC supplementation (generally 600–1,200 mg daily) can help slow progression and inhibit exacerbation of COPD, a condition that increases the risk of severe influenza and its complications.203


Selenium is an essential trace mineral that, when bound to the amino acid cysteine and incorporated into selenoproteins, plays a critical role in free radical quenching.208,209 During the immune response to viral infection, free radical production increases and antioxidant systems are downregulated, raising oxidative stress and contributing to cell and tissue damage.209,210 In a selenium deficient host, influenza infection raises oxidative stress to levels that not only exacerbate tissue damage but also cause changes in the viral genome that lead to more severe illness.208,209 Studies in animals and humans indicate selenium status also affects antiviral immune activation and inflammatory signaling, 208,211 and observational data suggest higher selenium intake may be linked to better outcomes in viral respiratory infections.

A two-year controlled trial in 725 elderly nursing home residents found those given a daily supplement providing 100 mcg selenium and 20 mg zinc had a better antibody response to influenza vaccination 15 to 17 months after starting the supplement than those given placebo. They also had fewer respiratory tract infections, but this difference was not statistically significant.212 Another trial that examined the effects of different doses and forms of selenium on immune response to the influenza vaccine in elderly individuals with borderline-low selenium levels found 100 mcg per day of yeast-derived selenium enhanced some aspects of the vaccine response, but the effects of higher and lower doses, as well as another supplement made from selenium-enriched onion, did not.213

Vitamin E

Vitamin E, a fat-soluble antioxidant nutrient, is concentrated in immune cells and plays an important role in immune function, partly due to its ability to protect immune cells from oxidative damage.214,215 Because of its important role in immune responsiveness, vitamin E (as alpha-tocopherol) is a key ingredient in a widely used influenza vaccine adjuvant called AS03. AS03 has been found to safely and effectively raise anti-influenza antibody production after vaccination, though it has been associated with more post-vaccine symptoms such as pain and fatigue.216,217

Supplementing with vitamin E, even in the absence of deficiency, may improve immune defense against upper respiratory infections. Because vitamin E appears to reverse some aspects of immune senescence, it may be most beneficial in the elderly.215,218,219 Clinical trials in elderly subjects have shown vitamin E, in doses of 50–800 mg (about 56–889 IU) of dl-α-tocopherol per day, can improve immune cell function.214

A study that examined data from 717 elderly patients hospitalized for pneumonia (the most common complication of influenza) found those taking vitamin E supplements had a lower risk of re-hospitalization during 90 days of monitoring.220 Two studies in elderly nursing home residents (with 153 participants in one study and 23 in the other) found those with higher vitamin E levels had better immune responsiveness to the influenza vaccine.221,222 However, a study in 61 healthy elderly subjects did not find a relationship between vitamin E levels and influenza vaccine response.223

Vitamin E supplementation may be particularly important among smokers. People who smoke cigarettes have higher levels of oxidative stress than non-smokers. Smokers also tend to have lower tissue and plasma levels of antioxidants like vitamin E.224,225 In a cohort of nearly 22,000 male smokers, incidence of common colds was slightly reduced among participants 65 years or older who had been taking vitamin E supplements long-term. However, this reduction was not evident in the cohort overall.226 In a secondary analysis of data from a trial in Finland, taking 50 mg of alpha-tocopherol daily for five to eight years was associated with a 69% reduced incidence of pneumonia among participants who smoked 5–19 cigarettes per day and regularly exercised. However, among those who smoked 20 or more cigarettes daily, vitamin E did not reduce pneumonia incidence. Among participants who quit smoking during the trial period, vitamin E supplementation was associated with 72% lower incidence of pneumonia compared with placebo.227


Echinacea species (Echinacea purpurea and E. angustifolia ) are used in herbal medicine to boost immune function and prevent and treat various acute infections. Echinacea has demonstrated antiviral effects against influenza viruses (including H1N1, H3N2, H5N1, and H7N7) in the laboratory.228

In a randomized controlled trial, 473 individuals in the early stage of the flu (ie, symptoms ≤48 hours) received either an echinacea-based drink mix (which also contained elderberry) for 10 days or oseltamivir for five days followed by five days of placebo. The trial was designed to determine whether the echinacea-based drink was inferior to oseltamivir as assessed by rate of symptomatic recovery. Over the 10 days, participants’ symptoms were assessed periodically. While recovery rate was similar in both groups, the echinacea group experienced fewer adverse events and the rate of complications was lower than in the oseltamivir group.229


Zinc is necessary for normal immune function, and increased risk of infection is a hallmark of zinc deficiency. In addition to its role in antiviral immune activity, zinc has direct antiviral actions against influenza virus and other common causes of upper respiratory tract infections, such as rhinoviruses.230 Interestingly, materials made with embedded zinc ions, which can be used to make facemasks and other personal protective equipment, have been shown to absorb and inactivate SARS-related viruses and influenza A virus H1N1 in the environment, keeping personal protective equipment virus-free and limiting viral spread.

Most research on zinc as a treatment for viral respiratory infections has focused on common colds. Multiple randomized controlled trials and several meta-analyses have found zinc lozenges, initiated within 24 hours of symptom onset and used in amounts providing 70–92 mg of elemental zinc per day, can effectively reduce the duration of common colds.231-233 Influenza viruses are frequent causes of upper respiratory infections that fall under the category of common cold, especially when symptoms are mild.234


Although best known for its role in circadian system regulation, melatonin is also produced by immune cells and participates in activating antimicrobial defenses, reducing inflammatory signaling, and lowering oxidative stress.235 Melatonin production diminishes with age, contributing to higher oxidative stress, inflammation, and infection susceptibility.

Melatonin has been shown to suppress pro-inflammatory cytokine release and reduce acute lung injury in animal models of viral infection. A preclinical animal model of influenza found that melatonin increased survival of mice infected with H1N1. Intriguingly, this animal model found melatonin plus ribavirin treatment led to better survival than ribavirin alone, suggesting melatonin may act as an adjuvant to antiviral therapy.236

In light of its safety and potential to inhibit a cytokine storm and reduce the severity of viral infections, there is growing interest in the possible preventive and therapeutic use of melatonin in influenza virus and other seasonal infections. The elderly and those with chronic medical conditions, who are at higher risk for severe complications from viral respiratory infections, may benefit most from regular use of 3–10 mg of melatonin at bedtime. Furthermore, some researchers have suggested particularly high doses of melatonin, ranging from 50 to 200 mg twice daily, might be helpful as part of treatment in patients hospitalized for acute respiratory symptoms suggestive of SARS-like illness.


Lactoferrin is an iron-binding protein made by cells such as those in secretory glands and activated neutrophils (a type of immune cell). It is found in most body fluids, including tears and breast milk, and lactoferrin derived from bovine whey is frequently used in supplements. Lactoferrin possesses immune-modulating effects, is capable of enhancing antimicrobial immune activity while reducing inflammation, and has exhibited a broad spectrum of activity against bacteria, fungi, protozoa, and viruses. Laboratory studies have shown lactoferrin inhibits certain viruses, including influenza viruses, from binding to cell receptor sites and entering host cells, and even suppresses viral replication inside infected cells.237 Lactoferrin, in its iron-free state (apo-lactoferrin), can sequester pro-oxidant iron, lowering oxidative stress and suppressing the growth of pathogens.238,239 In addition, lactoferrin decreases pro-inflammatory molecules released during the immune response to infection. Because of its immune-modulating and antiviral properties, lactoferrin has even attracted interest as a potential therapy for preventing or treating some acute infectious respiratory illnesses.237

A randomized controlled trial tested the effects of lactoferrin plus lactoperoxidase (another milk protein) in 407 healthy adults. The supplemented group used a lozenge providing 20 mg lactoferrin and 2.6 mg lactoperoxidase three times daily for eight weeks and the control group used no milk protein supplements. Although there were no significant differences in incidence of colds and flu, lactoferrin plus lactoperoxidase appeared to reduce the duration of fevers ≥38ºC (100.4ºF) in a subgroup of 190 participants who did not wear facemasks.240


Dehydroepiandrosterone (DHEA) is a steroid hormone synthesized by the adrenal gland that has a complex role in immune regulation and controlling the inflammatory process.241 Its effects on immune function appear to be related to its ability to act as a counterbalance to cortisol.242 DHEA levels decline with age, and this may be a contributing factor in immune senescence.243 In preclinical research, DHEA derivatives have been found to increase antiviral and antibacterial immune activity while suppressing inflammation, as well as protect laboratory animals from lethal influenza virus infection.244-246

Some evidence suggests higher DHEA levels are associated with a stronger response to the flu vaccine in older adults. In a placebo-controlled trial that included 78 elderly volunteers, a subcutaneous injection of 7.5 mg DHEA at the time of influenza vaccination improved the anti-influenza antibody response in a subgroup of participants with lower baseline DHEA and antibody levels.247

Vitamin A

Similar to vitamin D, metabolites of vitamin A, called retinoids, function as nuclear hormones. Vitamin A plays crucial roles in vision and development as well as in maintaining the integrity of the mucus layers in the respiratory and intestinal tract. Retinoids are also critically important for healthy differentiation, maturation, and function of cells of the innate immune system. Activation of vitamin A nuclear receptors exerts considerable influence on the immune response, and vitamin A deficiency has been linked with diminished resistance to viral infections and poor vaccine responses.248,249

In an animal model, vitamin A-deficient mice exhibited impaired immune response to influenza viral infection. The vitamin A-deficient mice displayed diminished T-cell recruitment and B-cell organization in lung lymphoid tissue and had higher viral titers than mice with sufficient levels of vitamin A. Moreover, the vitamin A-deficient mice suffered 100% mortality when exposed to a model of secondary bacterial lung infection.250 In diet-induced obese mice, vitamin A supplementation improved the antibody response to influenza vaccination and modulated the lung immune milieu.251 Other preclinical evidence suggests that, in the setting of vitamin A deficiency, retinoid treatment may ameliorate the hyperactive immune response that characterizes some infectious diseases.252

In a trial that enrolled 112 pregnant women, 76% of whom had low plasma vitamin A (retinol) concentrations, supplementation with 10,000 IU vitamin A weekly improved immune responses to influenza vaccination. At six months postpartum, women who received vitamin A had 39% higher hemagglutination inhibition antibody titers than women who received placebo.253 Another small trial showed that supplementation with vitamin A plus vitamin D improved influenza vaccine response in children who were deficient in both vitamins at baseline.254 However, one study of older adults in Wisconsin found serum vitamin A status was unrelated to influenza vaccine antibody response.255 Among Indonesian preschool children, vitamin A bolus dosing (200,000 IU) plus 10 mg zinc daily was associated with reduced number of days with respiratory tract infection symptoms.256


Garlic (Allium sativum) has a long history of use in preventing and treating infections, and has been shown to exert antimicrobial and immune-enhancing effects in numerous studies.257,258 In addition to improving the antiviral immune response, sulfur compounds from garlic have demonstrated direct antiviral action.259 In a controlled trial in 120 healthy volunteers, 2.56 grams of aged garlic extract per day for 90 days during cold and flu season resulted in improved immune cell function compared with placebo. In addition, aged garlic extract reduced the severity of cold and flu symptoms and number of workdays missed due to illness.260

French Oak

French oak wood extract has been found to reduce oxidative stress and improve energy level and stamina. One controlled trial enrolled 38 patients aged 65 to 75 years old who had experienced a 7‒10-day bout of influenza and been symptom-free for three days at the beginning of the trial. They were treated with either standard care plus 300 mg per day of a French oak wood extract or standard care alone for three weeks. After 10 days, those receiving the French oak wood extract had reduced heart rate, increased oxygen saturation, less weakness, and improved recovery from exertion; after three weeks, the supplemented group maintained faster recovery from exertions and had better sleep quality and improvements in some aspects of cognitive function.261

Disclaimer and Safety Information

This information (and any accompanying material) is not intended to replace the attention or advice of a physician or other qualified health care professional. Anyone who wishes to embark on any dietary, drug, exercise, or other lifestyle change intended to prevent or treat a specific disease or condition should first consult with and seek clearance from a physician or other qualified health care professional. Pregnant women in particular should seek the advice of a physician before using any protocol listed on this website. The protocols described on this website are for adults only, unless otherwise specified. Product labels may contain important safety information and the most recent product information provided by the product manufacturers should be carefully reviewed prior to use to verify the dose, administration, and contraindications. National, state, and local laws may vary regarding the use and application of many of the therapies discussed. The reader assumes the risk of any injuries. The authors and publishers, their affiliates and assigns are not liable for any injury and/or damage to persons arising from this protocol and expressly disclaim responsibility for any adverse effects resulting from the use of the information contained herein.

The protocols raise many issues that are subject to change as new data emerge. None of our suggested protocol regimens can guarantee health benefits. Life Extension has not performed independent verification of the data contained in the referenced materials, and expressly disclaims responsibility for any error in the literature.

  1. Boktor SW, Hafner JW. Influenza. StatPearls. StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC.; 2020.
  2. Dolin R. Seasonal influenza in adults: Transmission, clinical manifestations, and complications. UpToDate. Last reviewed 09/2020. . 2020;
  3. Chow EJ, Doyle JD, Uyeki TM. Influenza virus-related critical illness: prevention, diagnosis, treatment. Crit Care. Jun 12 2019;23(1):214. doi:10.1186/s13054-019-2491-9
  4. Krammer F, Smith GJD, Fouchier RAM, et al. Influenza. Nature reviews Disease primers. Jun 28 2018;4(1):3. doi:10.1038/s41572-018-0002-y
  5. CDC. Centers for Disease Control and Prevention. Disease Burden of Influenza. Available at . Last reveiwed 10/05/2020. Accessed 11/07/2020. . 2020;
  6. CDC. Centers for Disease Control and Prevention. Overview of Infuenza Testing Methods. Available at Last reviewed 08/31/2020. Accessed 11/13/2020. . 2020;
  7. Demurtas J, Celotto S, Beaudart C, et al. The efficacy and safety of influenza vaccination in older people: An umbrella review of evidence from meta-analyses of both observational and randomized controlled studies. Ageing Res Rev. Sep 2020;62:101118. doi:10.1016/j.arr.2020.101118
  8. Cheng Y, Cao X, Cao Z, et al. Effects of influenza vaccination on the risk of cardiovascular and respiratory diseases and all-cause mortality. Ageing Res Rev. Sep 2020;62:101124. doi:10.1016/j.arr.2020.101124
  9. Zachary KC. Treatment of seasonal influenza in adults. UpToDate. Last reviewed 09/2020. . 2020;
  10. McElhaney JE, Verschoor CP, Andrew MK, Haynes L, Kuchel GA, Pawelec G. The immune response to influenza in older humans: beyond immune senescence. Immunity & ageing : I & A. 2020;17:10. doi:10.1186/s12979-020-00181-1
  11. Keilich SR, Bartley JM, Haynes L. Diminished immune responses with aging predispose older adults to common and uncommon influenza complications. Cell Immunol. Nov 2019;345:103992. doi:10.1016/j.cellimm.2019.103992
  12. Dugan HL, Henry C, Wilson PC. Aging and influenza vaccine-induced immunity. Cell Immunol. Feb 2020;348:103998. doi:10.1016/j.cellimm.2019.103998
  13. Borkenhagen LK, Salman MD, Ma MJ, Gray GC. Animal influenza virus infections in humans: A commentary. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases . Nov 2019;88:113-119. doi:10.1016/j.ijid.2019.08.002
  14. Dolin R. Epidemiology of influenza. UpToDate. Last reviewed 09/2020. . 2020;
  15. CDC. Centers or Disease Control and Prevention. How the Flu Virus Can Change: “Drift” and “Shift”. Available at . Last rviewed 10/15/2019. Accessed 11/10/2020. . 2019;
  16. Voskarides K, Christaki E, Nikolopoulos GK. Influenza Virus-Host Co-evolution. A Predator-Prey Relationship? Front Immunol. 2018;9:2017. doi:10.3389/fimmu.2018.02017
  17. Ciminski K, Chase GP, Beer M, Schwemmle M. Influenza A Viruses: Understanding Human Host Determinants. Trends Mol Med. Oct 20 2020;doi:10.1016/j.molmed.2020.09.014
  18. Jilani TN, Jamil RT, Siddiqui AH. H1N1 Influenza. StatPearls. StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC.; 2020.
  19. Wasik BR, de Wit E, Munster V, Lloyd-Smith JO, Martinez-Sobrido L, Parrish CR. Onward transmission of viruses: how do viruses emerge to cause epidemics after spillover? Philosophical transactions of the Royal Society of London Series B, Biological sciences . Sep 30 2019;374(1782):20190017. doi:10.1098/rstb.2019.0017
  20. Nickol ME, Kindrachuk J. A year of terror and a century of reflection: perspectives on the great influenza pandemic of 1918-1919. BMC infectious diseases. Feb 6 2019;19(1):117. doi:10.1186/s12879-019-3750-8
  21. Kalil AC, Thomas PG. Influenza virus-related critical illness: pathophysiology and epidemiology. Crit Care. Jul 19 2019;23(1):258. doi:10.1186/s13054-019-2539-x
  22. Frank K, Paust S. Dynamic Natural Killer Cell and T Cell Responses to Influenza Infection. Frontiers in cellular and infection microbiology. 2020;10:425. doi:10.3389/fcimb.2020.00425
  23. Gutiérrez-Spillari L, Palma MG, Aceituno-Melgar J. Obesity, Cardiovascular Disease, and Influenza: How Are They Connected? Curr Trop Med Rep. Jul 6 2020:1-6. doi:10.1007/s40475-020-00207-0
  24. Frasca D, Blomberg BB. The Impact of Obesity and Metabolic Syndrome on Vaccination Success. Interdiscip Top Gerontol Geriatr. 2020;43:86-97. doi:10.1159/000504440
  25. Jiang C, Chen Q, Xie M. Smoking increases the risk of infectious diseases: A narrative review. Tobacco induced diseases. 2020;18:60. doi:10.18332/tid/123845
  26. Belok SH, Parikh R, Bernardo J, Kathuria H. E-cigarette, or vaping, product use-associated lung injury: a review. Pneumonia (Nathan). 2020;12:12. doi:10.1186/s41479-020-00075-2
  27. Chatham-Stephens K, Roguski K, Jang Y, et al. Characteristics of Hospitalized and Nonhospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, November 2019. MMWR Morb Mortal Wkly Rep. Nov 22 2019;68(46):1076-1080. doi:10.15585/mmwr.mm6846e1
  28. Madison MC, Landers CT, Gu BH, et al. Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine. J Clin Invest. Oct 1 2019;129(10):4290-4304. doi:10.1172/jci128531
  29. Jatlaoui TC, Wiltz JL, Kabbani S, et al. Update: Interim Guidance for Health Care Providers for Managing Patients with Suspected E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, November 2019. MMWR Morb Mortal Wkly Rep. Nov 22 2019;68(46):1081-1086. doi:10.15585/mmwr.mm6846e2
  30. Akkanti BH, Hussain R, Patel MK, et al. Deadly combination of Vaping-lnduced lung injury and Influenza: case report. Diagnostic pathology. Jul 9 2020;15(1):83. doi:10.1186/s13000-020-00998-w
  31. CDC. Centers for Disease Control and Prevention: Flu Symptoms and Complications. Available at . Last updated 08/31/20. Accessed 09/22/20. 2020;
  32. Sexton DJM, M. T. UpToDate. The common cold in adults: Diagnosis and clinical features. Last updated 12/27/19. Accessed 09/18/20. . 2019;
  33. Thomas M, Koutsothanasis GA, Bomar PA. Upper Respiratory Tract Infection. StatPearls. StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC.; 2020.
  34. Zlateva KT, De Vries JJC, Coenjaerts FEJ, et al. Prolonged shedding of rhinovirus and re-infection in adults with respiratory tract illness. European Respiratory Journal. 2014;44(1):169-177. doi:10.1183/09031936.00172113
  35. Peltola V, Waris M, Kainulainen L, Kero J, Ruuskanen O. Virus shedding after human rhinovirus infection in children, adults and patients with hypogammaglobulinaemia. Clinical Microbiology and Infection. 2013/07/01/ 2013;19(7):E322-E327. doi:
  36. Lau LL, Cowling BJ, Fang VJ, et al. Viral shedding and clinical illness in naturally acquired influenza virus infections. J Infect Dis. May 15 2010;201(10):1509-16. doi:10.1086/652241
  37. Kutter JS, Spronken MI, Fraaij PL, Fouchier RA, Herfst S. Transmission routes of respiratory viruses among humans. Current opinion in virology. Feb 2018;28:142-151. doi:10.1016/j.coviro.2018.01.001
  38. WHO. World Health Organization. International Travel and Health: Seasonal Influenza. Available at Accessed 11/17/2020. 2020;
  39. Hwang HS, Chang M, Kim YA. Influenza-Host Interplay and Strategies for Universal Vaccine Development. Vaccines. Sep 20 2020;8(3)doi:10.3390/vaccines8030548
  40. Klomp M, Ghosh S, Mohammed S, Nadeem Khan M. From virus to inflammation, how influenza promotes lung damage. Journal of leukocyte biology. Sep 8 2020;doi:10.1002/jlb.4ru0820-232r
  41. Pizzolla A, Wakim LM. Memory T Cell Dynamics in the Lung during Influenza Virus Infection. J Immunol. Jan 15 2019;202(2):374-381. doi:10.4049/jimmunol.1800979
  42. Guo XJ, Thomas PG. New fronts emerge in the influenza cytokine storm. Seminars in immunopathology. Jul 2017;39(5):541-550. doi:10.1007/s00281-017-0636-y
  43. Spel L, Martinon F. Detection of viruses by inflammasomes. Current opinion in virology. Nov 8 2020;46:59-64. doi:10.1016/j.coviro.2020.10.001
  44. Cantan B, Luyt CE, Martin-Loeches I. Influenza Infections and Emergent Viral Infections in Intensive Care Unit. Semin Respir Crit Care Med. Aug 2019;40(4):488-497. doi:10.1055/s-0039-1693497
  45. Gu Y, Hsu AC, Pang Z, et al. Role of the Innate Cytokine Storm Induced by the Influenza A Virus. Viral Immunol. Jul/Aug 2019;32(6):244-251. doi:10.1089/vim.2019.0032
  46. Yang Y, Tang H. Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia. Cellular & molecular immunology. Jul 2016;13(4):432-42. doi:10.1038/cmi.2016.1
  47. Sarda C, Palma P, Rello J. Severe influenza: overview in critically ill patients. Current opinion in critical care. Oct 2019;25(5):449-457. doi:10.1097/mcc.0000000000000638
  48. Chow EJ, Rolfes MA, O'Halloran A, et al. Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults : A Cross-sectional Study. Ann Intern Med. Oct 20 2020;173(8):605-613. doi:10.7326/m20-1509
  49. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. The New England journal of medicine. Jan 25 2018;378(4):345-353. doi:10.1056/NEJMoa1702090
  50. Aidoud A, Marlet J, Angoulvant D, Debacq C, Gavazzi G, Fougère B. Influenza vaccination as a novel means of preventing coronary heart disease: Effectiveness in older adults. Vaccine. Jul 6 2020;38(32):4944-4955. doi:10.1016/j.vaccine.2020.05.070
  51. CDC. Centers for Disease Control and Prevention. Influenza Virus Testing Methods. Available at Last reviewed 08/10/2020. Accessed 11/13/2020. . 2020;
  52. Dolin R. Diagnosis of seasonal influenza in adults. UpToDate. Last reviewed 05/31/2019. . 2020;
  53. CDC. Centers for Disease Control and Prevention. Influenza: Preventive Steps. Available at Last reviewed 09/25/2020. Accessed 11/17/2020. 2020;
  54. Kawahara T, Akiba I, Sakou M, Sakaguchi T, Taniguchi H. Inactivation of human and avian influenza viruses by potassium oleate of natural soap component through exothermic interaction. PLoS One. 2018;13(9):e0204908. doi:10.1371/journal.pone.0204908
  55. Saunders-Hastings P, Crispo JAG, Sikora L, Krewski D. Effectiveness of personal protective measures in reducing pandemic influenza transmission: A systematic review and meta-analysis. Epidemics. Sep 2017;20:1-20. doi:10.1016/j.epidem.2017.04.003
  56. Moncion K, Young K, Tunis M, Rempel S, Stirling R, Zhao L. Effectiveness of hand hygiene practices in preventing influenza virus infection in the community setting: A systematic review. Can Commun Dis Rep. Jan 3 2019;45(1):12-23. doi:10.14745/ccdr.v45i01a02
  57. Torner N, Soldevila N, Garcia JJ, et al. Effectiveness of non-pharmaceutical measures in preventing pediatric influenza: a case-control study. BMC Public Health. Jun 9 2015;15:543. doi:10.1186/s12889-015-1890-3
  58. Zhang D, Liu W, Yang P, et al. Factors associated with household transmission of pandemic (H1N1) 2009 among self-quarantined patients in Beijing, China. PLoS One. 2013;8(10):e77873. doi:10.1371/journal.pone.0077873
  59. Godoy P, Castilla J, Delgado-Rodríguez M, et al. Effectiveness of hand hygiene and provision of information in preventing influenza cases requiring hospitalization. Preventive medicine. Jun 2012;54(6):434-9. doi:10.1016/j.ypmed.2012.04.009
  60. CDC. Centers for Disease Control and Prevention. When and How to Wash Your Hands. Available at Last reviewed 09/01/2020. Accessed 11/17/2020. 2020;
  61. Liang M, Gao L, Cheng C, et al. Efficacy of face mask in preventing respiratory virus transmission: A systematic review and meta-analysis. Travel Med Infect Dis. Jul-Aug 2020;36:101751. doi:10.1016/j.tmaid.2020.101751
  62. Chaabna K, Doraiswamy S, Mamtani R, Cheema S. Facemask use in community settings to prevent respiratory infection transmission: a rapid review and meta-analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases . Sep 25 2020;doi:10.1016/j.ijid.2020.09.1434
  63. Moyad MA. Conventional and alternative medical advice for cold and flu prevention: what should be recommended and what should be avoided? Urologic nursing. Nov-Dec 2009;29(6):455-8.
  64. Kitamura T, Satomura K, Kawamura T, et al. Can we prevent influenza-like illnesses by gargling? Intern Med. 2007;46(18):1623-4. doi:10.2169/internalmedicine.46.0104
  65. Emamian MH, Hassani AM, Fateh M. Respiratory Tract Infections and its Preventive Measures among Hajj Pilgrims, 2010: A Nested Case Control Study. Int J Prev Med. Sep 2013;4(9):1030-5.
  66. Satomura K, Kitamura T, Kawamura T, et al. Prevention of upper respiratory tract infections by gargling: a randomized trial. Am J Prev Med. Nov 2005;29(4):302-7. doi:10.1016/j.amepre.2005.06.013
  67. Ide K, Yamada H, Kawasaki Y. Effect of gargling with tea and ingredients of tea on the prevention of influenza infection: a meta-analysis. BMC Public Health. May 12 2016;16:396. doi:10.1186/s12889-016-3083-0
  68. Tano L, Tano K. A daily nasal spray with saline prevents symptoms of rhinitis. Acta oto-laryngologica. Nov 2004;124(9):1059-62. doi:10.1080/00016480410017657
  69. Ramalingam S, Graham C, Dove J, Morrice L, Sheikh A. A pilot, open labelled, randomised controlled trial of hypertonic saline nasal irrigation and gargling for the common cold. Sci Rep. Jan 31 2019;9(1):1015. doi:10.1038/s41598-018-37703-3
  70. Hibberd PL. Seasonal influenza vaccination in adults. Uptodate. Last reviewed 09/2020. . 2020;
  71. CDC. Centers for Disease Control and Prevention. Influenza: Live Attenuated Infuenza Vaccine. Available at Last reviewed 09/02/2020. Accessed 11/17/2020. . 2020;
  72. Hollingsworth R, El Guerche-Séblain C, Tsai T, et al. Assessment of the benefits of seasonal influenza vaccination: Elements of a framework to interpret estimates of vaccine effectiveness and support robust decision-making and communication. Influenza Other Respir Viruses. Sep 3 2020;doi:10.1111/irv.12786
  73. Kulick ER, Canning M, Parikh NS, Elkind MSV, Boehme AK. Seasonality of Influenza-Like-Illness and Acute Cardiovascular Events Are Related Regardless of Vaccine Effectiveness. J Am Heart Assoc. Oct 20 2020;9(20):e016213. doi:10.1161/jaha.120.016213
  74. Rodrigues BS, Alves M, Duarte GS, Costa J, Pinto FJ, Caldeira D. The impact of influenza vaccination in patients with cardiovascular disease: An overview of systematic reviews. Trends Cardiovasc Med. Jun 12 2020;doi:10.1016/j.tcm.2020.06.003
  75. Modin D, Claggett B, Køber L, et al. Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort Study. Diabetes Care. Sep 2020;43(9):2226-2233. doi:10.2337/dc20-0229
  76. Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. Jama. Oct 23 2013;310(16):1711-20. doi:10.1001/jama.2013.279206
  77. Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. May 5 2015;(5):Cd005050. doi:10.1002/14651858.CD005050.pub3
  78. Zangiabadian M, Nejadghaderi SA, Mirsaeidi M, et al. Protective effect of influenza vaccination on cardiovascular diseases: a systematic review and meta-analysis. Sci Rep. Nov 26 2020;10(1):20656. doi:10.1038/s41598-020-77679-7
  79. Vardeny O, Kim K, Udell JA, et al. Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. Jama. Jan 5 2021;325(1):39-49. doi:10.1001/jama.2020.23649
  80. Lapi F, Marconi E, Simonetti M, et al. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly. Expert Rev Vaccines. Jun 2019;18(6):663-670. doi:10.1080/14760584.2019.1622418
  81. Trombetta CM, Gianchecchi E, Montomoli E. Influenza vaccines: Evaluation of the safety profile. Human vaccines & immunotherapeutics. Mar 4 2018;14(3):657-670. doi:10.1080/21645515.2017.1423153
  82. McNeil MM. Vaccine-Associated Anaphylaxis. Curr Treat Options Allergy. Sep 2019;6(3):297-308. doi:10.1007/s40521-019-00215-0
  83. CDC. Centers for Disease Control and Prevention. Guillian-Barre Syndrome and Vaccines. Available at ttps:// . Last reviewed 08/14/2020. Accessed 02/20/2021. 2020;
  84. Wagner A, Weinberger B. Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives. Front Immunol. 2020;11:717. doi:10.3389/fimmu.2020.00717
  85. Ko EJ, Kang SM. Immunology and efficacy of MF59-adjuvanted vaccines. Hum Vaccin Immunother. 2018;14(12):3041-3045. doi:10.1080/21645515.2018.1495301
  86. Chapman J, Arnold JK. Reye Syndrome. StatPearls. StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC.; 2020.
  87. Yang T. Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza. Ann Pharmacother. Jul 2019;53(7):754-759. doi:10.1177/1060028019826565
  88. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. The Cochrane database of systematic reviews. Apr 10 2014;2014(4):Cd008965. doi:10.1002/14651858.CD008965.pub4
  89. Pizzorno A, Padey B, Terrier O, Rosa-Calatrava M. Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy. Front Immunol. 2019;10:531. doi:10.3389/fimmu.2019.00531
  90. Rossignol JF. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral research. Oct 2014;110:94-103. doi:10.1016/j.antiviral.2014.07.014
  91. Gamiño-Arroyo AE, Guerrero ML, McCarthy S, et al. Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America . 2019;69(11):1903-1911. doi:10.1093/cid/ciz100
  92. Chase M, Grossestreuer AV, Liu X, Cocchi MN, Donnino MW. Atorvastatin Therapy in Acute Influenza Infection: A Randomized Clinical Trial. The Journal of emergency medicine. 2020;59(5):767-768. doi:10.1016/j.jemermed.2020.07.069
  93. Diaz A, Romero M, Vazquez T, Lechner S, Blomberg BB, Frasca D. Metformin improves in vivo and in vitro B cell function in individuals with obesity and Type-2 Diabetes. Vaccine. May 9 2017;35(20):2694-2700. doi:10.1016/j.vaccine.2017.03.078
  94. Saenwongsa W, Nithichanon A, Chittaganpitch M, et al. Metformin-induced suppression of IFN-α via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in type 2 diabetes. Sci Rep. Feb 24 2020;10(1):3229. doi:10.1038/s41598-020-60213-0
  95. Agarwal D, Schmader KE, Kossenkov AV, Doyle S, Kurupati R, Ertl HCJ. Immune response to influenza vaccination in the elderly is altered by chronic medication use. Immun Ageing. 2018;15:19. doi:10.1186/s12979-018-0124-9
  96. Moseley CE, Webster RG, Aldridge JR. Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respir Viruses. Sep 2010;4(5):307-11. doi:10.1111/j.1750-2659.2010.00155.x
  97. NLM. National Library of Medicine. Medline Plus: Cimetidine. Available at . Last updated 04/15/2020. Accessed 11/06/2020. 2020;
  98. Jafarzadeh A, Nemati M, Khorramdelazad H, Hassan ZM. Immunomodulatory properties of cimetidine: Its therapeutic potentials for treatment of immune-related diseases. International immunopharmacology. May 2019;70:156-166. doi:10.1016/j.intimp.2019.02.026
  99. Yip TF, Selim ASM, Lian I, Lee SM. Advancements in Host-Based Interventions for Influenza Treatment. Front Immunol. 2018;9:1547. doi:10.3389/fimmu.2018.01547
  100. Principi N, Camilloni B, Alunno A, Polinori I, Argentiero A, Esposito S. Drugs for Influenza Treatment: Is There Significant News? Front Med (Lausanne). 2019;6:109. doi:10.3389/fmed.2019.00109
  101. Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacology & therapeutics. May 2020;209:107512. doi:10.1016/j.pharmthera.2020.107512
  102. Madelain V, Mentré F, Baize S, et al. Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. CPT Pharmacometrics Syst Pharmacol. May 2020;9(5):258-271. doi:10.1002/psp4.12510
  103. Toots M, Plemper RK. Next-generation direct-acting influenza therapeutics. Translational research : the journal of laboratory and clinical medicine . Jun 2020;220:33-42. doi:10.1016/j.trsl.2020.01.005
  104. Vogel OA, Manicassamy B. Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics. Front Microbiol. 2020;11:135. doi:10.3389/fmicb.2020.00135
  105. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. Jan 1 2015;211(1):80-90. doi:10.1093/infdis/jiu396
  106. Xu Z, Zhou J, Huang Y, et al. Efficacy of convalescent plasma for the treatment of severe influenza. Crit Care. Jul 29 2020;24(1):469. doi:10.1186/s13054-020-03189-7
  107. Davey RT, Jr., Fernández-Cruz E, Markowitz N, et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respir Med. Nov 2019;7(11):951-963. doi:10.1016/s2213-2600(19)30253-x
  108. Klinkhammer J, Schnepf D, Ye L, et al. IFN-λ prevents influenza virus spread from the upper airways to the lungs and limits virus transmission. Elife. Apr 13 2018;7doi:10.7554/eLife.33354
  109. Syedbasha M, Egli A. Interferon Lambda: Modulating Immunity in Infectious Diseases. Front Immunol. 2017;8:119. doi:10.3389/fimmu.2017.00119
  110. Galani IE, Triantafyllia V, Eleminiadou EE, et al. Interferon-λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness. Immunity. May 16 2017;46(5):875-890.e6. doi:10.1016/j.immuni.2017.04.025
  111. Rich HE, McCourt CC, Zheng WQ, et al. Interferon Lambda Inhibits Bacterial Uptake during Influenza Superinfection. Infect Immun. Mar 2019;87(5)doi:10.1128/iai.00114-19
  112. Sun W, Luo T, Liu W, Li J. Progress in the Development of Universal Influenza Vaccines. Viruses. Sep 17 2020;12(9)doi:10.3390/v12091033
  113. Corder BN, Bullard BL, Poland GA, Weaver EA. A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade. Viruses. Oct 20 2020;12(10)doi:10.3390/v12101186
  114. Honce R, Schultz-Cherry S. Impact of Obesity on Influenza A Virus Pathogenesis, Immune Response, and Evolution. Front Immunol. 2019;10:1071. doi:10.3389/fimmu.2019.01071
  115. Calder PC, Carr AC, Gombart AF, Eggersdorfer M. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections. Nutrients. Apr 23 2020;12(4)doi:10.3390/nu12041181
  116. Gleeson M. Immunological aspects of sport nutrition. Immunology and cell biology. Feb 2016;94(2):117-23. doi:10.1038/icb.2015.109
  117. Trompette A, Gollwitzer ES, Pattaroni C, et al. Dietary Fiber Confers Protection against Flu by Shaping Ly6c(-) Patrolling Monocyte Hematopoiesis and CD8(+) T Cell Metabolism. Immunity. May 15 2018;48(5):992-1005.e8. doi:10.1016/j.immuni.2018.04.022
  118. Zima V, Radilová K, Kožíšek M, et al. Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors. European journal of medicinal chemistry. Dec 15 2020;208:112754. doi:10.1016/j.ejmech.2020.112754
  119. Hamida RS, Shami A, Ali MA, Almohawes ZN, Mohammed AE, Bin-Meferij MM. Kefir: A protective dietary supplementation against viral infection. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie . Nov 11 2020;133:110974. doi:10.1016/j.biopha.2020.110974
  120. Grande AJ, Keogh J, Silva V, Scott AM. Exercise versus no exercise for the occurrence, severity, and duration of acute respiratory infections. The Cochrane database of systematic reviews. Apr 4 2020;4(4):Cd010596. doi:10.1002/14651858.CD010596.pub3
  121. Nieman DC, Wentz LM. The compelling link between physical activity and the body's defense system. J Sport Health Sci. May 2019;8(3):201-217. doi:10.1016/j.jshs.2018.09.009
  122. Woods JA, Keylock KT, Lowder T, et al. Cardiovascular exercise training extends influenza vaccine seroprotection in sedentary older adults: the immune function intervention trial. J Am Geriatr Soc. Dec 2009;57(12):2183-91. doi:10.1111/j.1532-5415.2009.02563.x
  123. Taylor DJ, Kelly K, Kohut ML, Song KS. Is Insomnia a Risk Factor for Decreased Influenza Vaccine Response? Behavioral sleep medicine. Jul-Aug 2017;15(4):270-287. doi:10.1080/15402002.2015.1126596
  124. Besedovsky L, Lange T, Haack M. The Sleep-Immune Crosstalk in Health and Disease. Physiol Rev. Jul 1 2019;99(3):1325-1380. doi:10.1152/physrev.00010.2018
  125. Hayney MS, Coe CL, Muller D, et al. Age and psychological influences on immune responses to trivalent inactivated influenza vaccine in the meditation or exercise for preventing acute respiratory infection (MEPARI) trial. Human vaccines & immunotherapeutics. 2014;10(1):83-91. doi:10.4161/hv.26661
  126. Wong SY, Wong CK, Chan FW, et al. Chronic psychosocial stress: does it modulate immunity to the influenza vaccine in Hong Kong Chinese elderly caregivers? Age (Dordr). Aug 2013;35(4):1479-93. doi:10.1007/s11357-012-9449-z
  127. Pedersen AF, Zachariae R, Bovbjerg DH. Psychological stress and antibody response to influenza vaccination: a meta-analysis. Brain Behav Immun. May 2009;23(4):427-33. doi:10.1016/j.bbi.2009.01.004
  128. Smolderen KG, Vingerhoets AJ, Croon MA, Denollet J. Personality, psychological stress, and self-reported influenza symptomatology. BMC Public Health. Nov 23 2007;7:339. doi:10.1186/1471-2458-7-339
  129. Shahbazi R, Yasavoli-Sharahi H, Alsadi N, Ismail N, Matar C. Probiotics in Treatment of Viral Respiratory Infections and Neuroinflammatory Disorders. Molecules (Basel, Switzerland). Oct 22 2020;25(21)doi:10.3390/molecules25214891
  130. Yamamoto Y, Saruta J, Takahashi T, et al. Effect of ingesting yogurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 on influenza virus-bound salivary IgA in elderly residents of nursing homes: a randomized controlled trial. Acta odontologica Scandinavica. Oct 2019;77(7):517-524. doi:10.1080/00016357.2019.1609697
  131. Kinoshita T, Maruyama K, Suyama K, et al. The effects of OLL1073R-1 yogurt intake on influenza incidence and immunological markers among women healthcare workers: a randomized controlled trial. Food Funct. Dec 11 2019;10(12):8129-8136. doi:10.1039/c9fo02128k
  132. Wang B, Hylwka T, Smieja M, Surrette M, Bowdish DME, Loeb M. Probiotics to Prevent Respiratory Infections in Nursing Homes: A Pilot Randomized Controlled Trial. J Am Geriatr Soc. Jul 2018;66(7):1346-1352. doi:10.1111/jgs.15396
  133. Waki N, Matsumoto M, Fukui Y, Suganuma H. Effects of probiotic Lactobacillus brevis KB290 on incidence of influenza infection among schoolchildren: an open-label pilot study. Lett Appl Microbiol. Dec 2014;59(6):565-71. doi:10.1111/lam.12340
  134. Zhang H, Yeh C, Jin Z, et al. Prospective study of probiotic supplementation results in immune stimulation and improvement of upper respiratory infection rate. Synth Syst Biotechnol. Jun 2018;3(2):113-120. doi:10.1016/j.synbio.2018.03.001
  135. Langkamp-Henken B, Rowe CC, Ford AL, et al. Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-controlled study. The British journal of nutrition. Feb 14 2015;113(3):426-34. doi:10.1017/s0007114514003997
  136. Araujo GV, Oliveira Junior MH, Peixoto DM, Sarinho ES. Probiotics for the treatment of upper and lower respiratory-tract infections in children: systematic review based on randomized clinical trials. Jornal de pediatria. Sep-Oct 2015;91(5):413-27. doi:10.1016/j.jped.2015.03.002
  137. Pregliasco F, Anselmi G, Fonte L, Giussani F, Schieppati S, Soletti L. A new chance of preventing winter diseases by the administration of synbiotic formulations. Journal of clinical gastroenterology. Sep 2008;42 Suppl 3 Pt 2:S224-33. doi:10.1097/MCG.0b013e31817e1c91
  138. Chan CKY, Tao J, Chan OS, Li HB, Pang H. Preventing Respiratory Tract Infections by Synbiotic Interventions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr. Jul 1 2020;11(4):979-988. doi:10.1093/advances/nmaa003
  139. Fonollá J, Gracián C, Maldonado-Lobón JA, et al. Effects of Lactobacillus coryniformis K8 CECT5711 on the immune response to influenza vaccination and the assessment of common respiratory symptoms in elderly subjects: a randomized controlled trial. European journal of nutrition. Feb 2019;58(1):83-90. doi:10.1007/s00394-017-1573-1
  140. Yeh TL, Shih PC, Liu SJ, et al. The influence of prebiotic or probiotic supplementation on antibody titers after influenza vaccination: a systematic review and meta-analysis of randomized controlled trials. Drug design, development and therapy. 2018;12:217-230. doi:10.2147/dddt.S155110
  141. Maruyama M, Abe R, Shimono T, Iwabuchi N, Abe F, Xiao JZ. The effects of non-viable Lactobacillus on immune function in the elderly: a randomised, double-blind, placebo-controlled study. International journal of food sciences and nutrition. 2016;67(1):67-73. doi:10.3109/09637486.2015.1126564
  142. Jesenak M, Urbancikova I, Banovcin P. Respiratory Tract Infections and the Role of Biologically Active Polysaccharides in Their Management and Prevention. Nutrients. Jul 20 2017;9(7)doi:10.3390/nu9070779
  143. Ciecierska A, Drywien ME, Hamulka J, Sadkowski T. Nutraceutical functions of beta-glucans in human nutrition. Roczniki Panstwowego Zakladu Higieny. 2019;70(4):315-324. doi:10.32394/rpzh.2019.0082
  144. Han B, Baruah K, Cox E, Vanrompay D, Bossier P. Structure-Functional Activity Relationship of β-Glucans From the Perspective of Immunomodulation: A Mini-Review. Front Immunol. 2020;11:658. doi:10.3389/fimmu.2020.00658
  145. Di Sotto A, Vitalone A, Di Giacomo S. Plant-Derived Nutraceuticals and Immune System Modulation: An Evidence-Based Overview. Vaccines. Aug 22 2020;8(3)doi:10.3390/vaccines8030468
  146. Wang M, Zhang L, Yang R, et al. Improvement of immune responses to influenza vaccine (H5N1) by sulfated yeast beta-glucan. International journal of biological macromolecules. Dec 2016;93(Pt A):203-207. doi:10.1016/j.ijbiomac.2016.06.057
  147. Vetvicka V, Vetvickova J. Glucan supplementation enhances the immune response against an influenza challenge in mice. Ann Transl Med. Feb 2015;3(2):22. doi:10.3978/j.issn.2305-5839.2015.01.08
  148. Dai X, Stanilka JM, Rowe CA, et al. Consuming Lentinula edodes (Shiitake) Mushrooms Daily Improves Human Immunity: A Randomized Dietary Intervention in Healthy Young Adults. Journal of the American College of Nutrition. 2015/11/02 2015;34(6):478-487. doi:10.1080/07315724.2014.950391
  149. Mah E, Kaden VN, Kelley KM, Liska DJ. Beverage Containing Dispersible Yeast β-Glucan Decreases Cold/Flu Symptomatic Days After Intense Exercise: A Randomized Controlled Trial. Journal of dietary supplements. 2020;17(2):200-210. doi:10.1080/19390211.2018.1495676
  150. McFarlin BK, Carpenter KC, Davidson T, McFarlin MA. Baker's yeast beta glucan supplementation increases salivary IgA and decreases cold/flu symptomatic days after intense exercise. Journal of dietary supplements. Sep 2013;10(3):171-83. doi:10.3109/19390211.2013.820248
  151. Jesenak M, Majtan J, Rennerova Z, Kyselovic J, Banovcin P, Hrubisko M. Immunomodulatory effect of pleuran (β-glucan from Pleurotus ostreatus) in children with recurrent respiratory tract infections. International immunopharmacology. Feb 2013;15(2):395-9. doi:10.1016/j.intimp.2012.11.020
  152. Evans M, Falcone PH, Crowley DC, et al. Effect of a Euglena gracilis Fermentate on Immune Function in Healthy, Active Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. Dec 3 2019;11(12)doi:10.3390/nu11122926
  153. Dharsono T, Rudnicka K, Wilhelm M, Schoen C. Effects of Yeast (1,3)-(1,6)-Beta-Glucan on Severity of Upper Respiratory Tract Infections: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Subjects. J Am Coll Nutr. Jan 2019;38(1):40-50. doi:10.1080/07315724.2018.1478339
  154. Auinger A, Riede L, Bothe G, Busch R, Gruenwald J. Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body's defence against pathogens: a double-blind, randomized, placebo-controlled, multicentric study in healthy subjects. European journal of nutrition. Dec 2013;52(8):1913-8. doi:10.1007/s00394-013-0492-z
  155. Talbott SM, Talbott JA. Baker's yeast beta-glucan supplement reduces upper respiratory symptoms and improves mood state in stressed women. J Am Coll Nutr. Aug 2012;31(4):295-300.
  156. Sen S, Mansell TJ. Yeasts as probiotics: Mechanisms, outcomes, and future potential. Fungal Genetics and Biology. 2020/04/01/ 2020;137:103333. doi:
  157. Moyad MA, Robinson LE, Zawada ET, et al. Immunogenic yeast-based fermentate for cold/flu-like symptoms in nonvaccinated individuals. Journal of alternative and complementary medicine (New York, NY). 2010;16(2):213-218. doi:10.1089/acm.2009.0310
  158. Moyad MA, Robinson LE, Zawada ET, Jr., et al. Effects of a modified yeast supplement on cold/flu symptoms. Urologic nursing. Feb 2008;28(1):50-5.
  159. Iqbal H, Rhee DK. Ginseng alleviates microbial infections of the respiratory tract: a review. J Ginseng Res. Mar 2020;44(2):194-204. doi:10.1016/j.jgr.2019.12.001
  160. Antonelli M, Donelli D, Firenzuoli F. Ginseng integrative supplementation for seasonal acute upper respiratory infections: A systematic review and meta-analysis. Complementary therapies in medicine. Aug 2020;52:102457. doi:10.1016/j.ctim.2020.102457
  161. McElhaney JE, Goel V, Toane B, Hooten J, Shan JJ. Efficacy of COLD-fX in the prevention of respiratory symptoms in community-dwelling adults: a randomized, double-blinded, placebo controlled trial. Journal of alternative and complementary medicine (New York, NY). Mar 2006;12(2):153-7. doi:10.1089/acm.2006.12.153
  162. McElhaney JE, Gravenstein S, Cole SK, et al. A placebo-controlled trial of a proprietary extract of North American ginseng (CVT-E002) to prevent acute respiratory illness in institutionalized older adults. J Am Geriatr Soc. Jan 2004;52(1):13-9. doi:10.1111/j.1532-5415.2004.52004.x
  163. Lee CS, Lee JH, Oh M, et al. Preventive effect of Korean red ginseng for acute respiratory illness: a randomized and double-blind clinical trial. J Korean Med Sci. Dec 2012;27(12):1472-8. doi:10.3346/jkms.2012.27.12.1472
  164. Scaglione F, Cattaneo G, Alessandria M, Cogo R. Efficacy and safety of the standardised Ginseng extract G115 for potentiating vaccination against the influenza syndrome and protection against the common cold [corrected]. Drugs under experimental and clinical research. 1996;22(2):65-72.
  165. Furushima D, Ide K, Yamada H. Effect of Tea Catechins on Influenza Infection and the Common Cold with a Focus on Epidemiological/Clinical Studies. Molecules (Basel, Switzerland). Jul 20 2018;23(7)doi:10.3390/molecules23071795
  166. Ide K, Kawasaki Y, Kawakami K, Yamada H. Anti-influenza Virus Effects of Catechins: A Molecular and Clinical Review. Curr Med Chem. 2016;23(42):4773-4783. doi:10.2174/0929867324666161123091010
  167. Rowe CA, Nantz MP, Bukowski JF, Percival SS. Specific formulation of Camellia sinensis prevents cold and flu symptoms and enhances gamma,delta T cell function: a randomized, double-blind, placebo-controlled study. J Am Coll Nutr. Oct 2007;26(5):445-52. doi:10.1080/07315724.2007.10719634
  168. Furushima D, Nishimura T, Takuma N, et al. Prevention of Acute Upper Respiratory Infections by Consumption of Catechins in Healthcare Workers: A Randomized, Placebo-Controlled Trial. Nutrients. Dec 18 2019;12(1)doi:10.3390/nu12010004
  169. Matsumoto K, Yamada H, Takuma N, Niino H, Sagesaka YM. Effects of green tea catechins and theanine on preventing influenza infection among healthcare workers: a randomized controlled trial. BMC Complement Altern Med. 2011;11:15. doi:10.1186/1472-6882-11-15
  170. Nanri A, Nakamoto K, Sakamoto N, Imai T, Mizoue T. Green tea consumption and influenza infection among Japanese employees. European journal of clinical nutrition. Nov 2 2020;doi:10.1038/s41430-020-00792-3
  171. Delabre RM, Lapidus N, Salez N, Mansiaux Y, de Lamballerie X, Carrat F. Risk factors of pandemic influenza A/H1N1 in a prospective household cohort in the general population: results from the CoPanFlu-France cohort. Influenza Other Respir Viruses. Jan 2015;9(1):43-50. doi:10.1111/irv.12294
  172. Park M, Yamada H, Matsushita K, et al. Green tea consumption is inversely associated with the incidence of influenza infection among schoolchildren in a tea plantation area of Japan. J Nutr. Oct 2011;141(10):1862-70. doi:10.3945/jn.110.137547
  173. Młynarczyk K, Walkowiak-Tomczak D, Łysiak GP. Bioactive properties of Sambucus nigra L. as a functional ingredient for food and pharmaceutical industry. J Funct Foods. Jan 2018;40:377-390. doi:10.1016/j.jff.2017.11.025
  174. Shahsavandi S, Ebrahimi MM, Hasaninejad Farahani A. Interfering With Lipid Raft Association: A Mechanism to Control Influenza Virus Infection By Sambucus Nigra. Iranian journal of pharmaceutical research : IJPR. Summer 2017;16(3):1147-1154.
  175. Kinoshita E, Hayashi K, Katayama H, Hayashi T, Obata A. Anti-influenza virus effects of elderberry juice and its fractions. Bioscience, biotechnology, and biochemistry. 2012;76(9):1633-8. doi:10.1271/bbb.120112
  176. Krawitz C, Mraheil MA, Stein M, et al. Inhibitory activity of a standardized elderberry liquid extract against clinically-relevant human respiratory bacterial pathogens and influenza A and B viruses. BMC Complement Altern Med. Feb 25 2011;11:16. doi:10.1186/1472-6882-11-16
  177. Glatthaar-Saalmüller B, Rauchhaus U, Rode S, Haunschild J, Saalmüller A. Antiviral activity in vitro of two preparations of the herbal medicinal product Sinupret® against viruses causing respiratory infections. Phytomedicine. Dec 15 2011;19(1):1-7. doi:10.1016/j.phymed.2011.10.010
  178. Zakay-Rones Z, Thom E, Wollan T, Wadstein J. Randomized study of the efficacy and safety of oral elderberry extract in the treatment of influenza A and B virus infections. The Journal of international medical research. Mar-Apr 2004;32(2):132-40. doi:10.1177/147323000403200205
  179. Zakay-Rones Z, Varsano N, Zlotnik M, et al. Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elderberry extract (Sambucus nigra L.) during an outbreak of influenza B Panama. J Altern Complement Med. Winter 1995;1(4):361-9. doi:10.1089/acm.1995.1.361
  180. Harnett J, Oakes K, Carè J, et al. The effects of Sambucus nigra berry on acute respiratory viral infections: A rapid review of clinical studies. Adv Integr Med. Dec 2020;7(4):240-246. doi:10.1016/j.aimed.2020.08.001
  181. Hawkins J, Baker C, Cherry L, Dunne E. Black elderberry (Sambucus nigra) supplementation effectively treats upper respiratory symptoms: A meta-analysis of randomized, controlled clinical trials. Complement Ther Med. Feb 2019;42:361-365. doi:10.1016/j.ctim.2018.12.004
  182. Macknin M, Wolski K, Negrey J, Mace S. Elderberry Extract Outpatient Influenza Treatment for Emergency Room Patients Ages 5 and Above: a Randomized, Double-Blind, Placebo-Controlled Trial. J Gen Intern Med. Nov 2020;35(11):3271-3277. doi:10.1007/s11606-020-06170-w
  183. Hu XY, Wu RH, Logue M, et al. Andrographis paniculata (Chuān Xīn Lián) for symptomatic relief of acute respiratory tract infections in adults and children: A systematic review and meta-analysis. PLoS One. 2017;12(8):e0181780. doi:10.1371/journal.pone.0181780
  184. Hossain MS, Urbi Z, Sule A, Hafizur Rahman KM. Andrographis paniculata (Burm. f.) Wall. ex Nees: a review of ethnobotany, phytochemistry, and pharmacology. TheScientificWorldJournal. 2014;2014:274905. doi:10.1155/2014/274905
  185. Jayakumar T, Hsieh CY, Lee JJ, Sheu JR. Experimental and Clinical Pharmacology of Andrographis paniculata and Its Major Bioactive Phytoconstituent Andrographolide. Evidence-based complementary and alternative medicine : eCAM. 2013;2013:846740. doi:10.1155/2013/846740
  186. Seniya C, Shrivastava S, Singh SK, Khan GJ. Analyzing the interaction of a herbal compound Andrographolide from Andrographis paniculata as a folklore against swine flu (H1N1). Asian Pac J Trop Dis. Sep 2014;4:S624-s630. doi:10.1016/s2222-1808(14)60692-7
  187. Ding Y, Chen L, Wu W, Yang J, Yang Z, Liu S. Andrographolide inhibits influenza A virus-induced inflammation in a murine model through NF-κB and JAK-STAT signaling pathway. Microbes Infect. Dec 2017;19(12):605-615. doi:10.1016/j.micinf.2017.08.009
  188. Cai W, Chen S, Li Y, et al. 14-Deoxy-11,12-didehydroandrographolide attenuates excessive inflammatory responses and protects mice lethally challenged with highly pathogenic A(H5N1) influenza viruses. Antiviral research. Sep 2016;133:95-105. doi:10.1016/j.antiviral.2016.07.020
  189. Suriyo T, Pholphana N, Ungtrakul T, et al. Clinical Parameters following Multiple Oral Dose Administration of a Standardized Andrographis paniculata Capsule in Healthy Thai Subjects. Planta Med. Jun 2017;83(9):778-789. doi:10.1055/s-0043-104382
  190. Kulichenko LL, Kireyeva LV, Malyshkina EN, Wikman G. A randomized, controlled study of Kan Jang versus amantadine in the treatment of influenza in Volgograd. Journal of herbal pharmacotherapy. 2003;3(1):77-93.
  191. Wagner L, Cramer H, Klose P, et al. Herbal Medicine for Cough: a Systematic Review and Meta-Analysis. Forschende Komplementarmedizin (2006). 2015;22(6):359-68. doi:10.1159/000442111
  192. Kim Y, Kim H, Bae S, et al. Vitamin C Is an Essential Factor on the Anti-viral Immune Responses through the Production of Interferon-α/β at the Initial Stage of Influenza A Virus (H3N2) Infection. Immune Netw. Apr 2013;13(2):70-4. doi:10.4110/in.2013.13.2.70
  193. Hemilä H. Vitamin C and Infections. Nutrients. Mar 29 2017;9(4)doi:10.3390/nu9040339
  194. Colunga Biancatelli RML, Berrill M, Marik PE. The antiviral properties of vitamin C. Expert review of anti-infective therapy. Feb 2020;18(2):99-101. doi:10.1080/14787210.2020.1706483
  195. Uchide N, Toyoda H. Antioxidant therapy as a potential approach to severe influenza-associated complications. Molecules (Basel, Switzerland). Feb 28 2011;16(3):2032-52. doi:10.3390/molecules16032032
  196. Siddiqui M, Manansala JS, Abdulrahman HA, et al. Immune Modulatory Effects of Vitamin D on Viral Infections. Nutrients. Sep 21 2020;12(9)doi:10.3390/nu12092879
  197. Gruber-Bzura BM. Vitamin D and Influenza-Prevention or Therapy? International journal of molecular sciences. Aug 16 2018;19(8)doi:10.3390/ijms19082419
  198. Greiller CL, Martineau AR. Modulation of the immune response to respiratory viruses by vitamin D. Nutrients. May 29 2015;7(6):4240-70. doi:10.3390/nu7064240
  199. Zisi D, Challa A, Makis A. The association between vitamin D status and infectious diseases of the respiratory system in infancy and childhood. Hormones (Athens, Greece). Dec 2019;18(4):353-363. doi:10.1007/s42000-019-00155-z
  200. Pham H, Rahman A, Majidi A, Waterhouse M, Neale RE. Acute Respiratory Tract Infection and 25-Hydroxyvitamin D Concentration: A Systematic Review and Meta-Analysis. International journal of environmental research and public health. Aug 21 2019;16(17)doi:10.3390/ijerph16173020
  201. Sabetta JR, DePetrillo P, Cipriani RJ, Smardin J, Burns LA, Landry ML. Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PLoS One. Jun 14 2010;5(6):e11088. doi:10.1371/journal.pone.0011088
  202. Martineau AR, Jolliffe DA, Greenberg L, et al. Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis. Health technology assessment (Winchester, England). Jan 2019;23(2):1-44. doi:10.3310/hta23020
  203. Millea PJ. N-acetylcysteine: multiple clinical applications. American family physician. Aug 1 2009;80(3):265-9.
  204. McCarty MF, DiNicolantonio JJ. An increased need for dietary cysteine in support of glutathione synthesis may underlie the increased risk for mortality associated with low protein intake in the elderly. Age (Dordr). Oct 2015;37(5):96. doi:10.1007/s11357-015-9823-8
  205. Hui DS, Lee N. Adjunctive therapies and immunomodulating agents for severe influenza. Influenza Other Respir Viruses. Nov 2013;7 Suppl 3(Suppl 3):52-9. doi:10.1111/irv.12171
  206. Hui DS, Lee N, Chan PK, Beigel JH. The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral research. Feb 2018;150:202-216. doi:10.1016/j.antiviral.2018.01.002
  207. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. The European respiratory journal. Jul 1997;10(7):1535-41.
  208. Steinbrenner H, Al-Quraishy S, Dkhil MA, Wunderlich F, Sies H. Dietary selenium in adjuvant therapy of viral and bacterial infections. Adv Nutr. Jan 2015;6(1):73-82. doi:10.3945/an.114.007575
  209. Guillin OM, Vindry C, Ohlmann T, Chavatte L. Selenium, Selenoproteins and Viral Infection. Nutrients. Sep 4 2019;11(9)doi:10.3390/nu11092101
  210. Erkekoğlu P, Aşçı A, Ceyhan M, et al. Selenium levels, selenoenzyme activities and oxidant/antioxidant parameters in H1N1-infected children. The Turkish journal of pediatrics. May-Jun 2013;55(3):271-82.
  211. Hawkes WC, Kelley DS, Taylor PC. The effects of dietary selenium on the immune system in healthy men. Biol Trace Elem Res. Sep 2001;81(3):189-213. doi:10.1385/bter:81:3:189
  212. Girodon F, Galan P, Monget AL, et al. Impact of trace elements and vitamin supplementation on immunity and infections in institutionalized elderly patients: a randomized controlled trial. MIN. VIT. AOX. geriatric network. Arch Intern Med. Apr 12 1999;159(7):748-54.
  213. Ivory K, Prieto E, Spinks C, et al. Selenium supplementation has beneficial and detrimental effects on immunity to influenza vaccine in older adults. Clin Nutr. Apr 2017;36(2):407-415. doi:10.1016/j.clnu.2015.12.003
  214. Pae M, Meydani SN, Wu D. The role of nutrition in enhancing immunity in aging. Aging Dis. Feb 2012;3(1):91-129.
  215. Lewis ED, Meydani SN, Wu D. Regulatory role of vitamin E in the immune system and inflammation. IUBMB Life. Apr 2019;71(4):487-494. doi:10.1002/iub.1976
  216. Hauser MI, Muscatello DJ, Soh ACY, Dwyer DE, Turner RM. An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines. Vaccine. Jul 18 2019;37(31):4246-4255. doi:10.1016/j.vaccine.2019.06.039
  217. Cohet C, van der Most R, Bauchau V, et al. Safety of AS03-adjuvanted influenza vaccines: A review of the evidence. Vaccine. May 21 2019;37(23):3006-3021. doi:10.1016/j.vaccine.2019.04.048
  218. Wu D, Meydani SN. Age-associated changes in immune function: impact of vitamin E intervention and the underlying mechanisms. Endocr Metab Immune Disord Drug Targets. 2014;14(4):283-9.
  219. Wu D, Meydani SN. Age-associated changes in immune and inflammatory responses: impact of vitamin E intervention. Journal of leukocyte biology. Oct 2008;84(4):900-14. doi:10.1189/jlb.0108023
  220. Neupane B, Walter SD, Krueger P, Marrie T, Loeb M. Predictors of inhospital mortality and re-hospitalization in older adults with community-acquired pneumonia: a prospective cohort study. BMC geriatrics. 2010;10:22. doi:10.1186/1471-2318-10-22
  221. Hara M, Tanaka K, Hirota Y. Immune response to influenza vaccine in healthy adults and the elderly: association with nutritional status. Vaccine. Feb 10 2005;23(12):1457-63. doi:10.1016/j.vaccine.2004.09.022
  222. Fülöp T, Jr., Wagner JR, Khalil A, Weber J, Trottier L, Payette H. Relationship between the response to influenza vaccination and the nutritional status in institutionalized elderly subjects. The journals of gerontology Series A, Biological sciences and medical sciences . Feb 1999;54(2):M59-64. doi:10.1093/gerona/54.2.m59
  223. Gardner EM, Bernstein ED, Popoff KA, Abrutyn E, Gross P, Murasko DM. Immune response to influenza vaccine in healthy elderly: lack of association with plasma beta-carotene, retinol, alpha-tocopherol, or zinc. Mech Ageing Dev. Aug 15 2000;117(1-3):29-45. doi:10.1016/s0047-6374(00)00134-2
  224. Mezzetti A, Lapenna D, Pierdomenico SD, et al. Vitamins E, C and lipid peroxidation in plasma and arterial tissue of smokers and non-smokers. Atherosclerosis. Jan 6 1995;112(1):91-9. doi:10.1016/0021-9150(94)05403-6
  225. Pacht ER, Kaseki H, Mohammed JR, Cornwell DG, Davis WB. Deficiency of vitamin E in the alveolar fluid of cigarette smokers. Influence on alveolar macrophage cytotoxicity. J Clin Invest. Mar 1986;77(3):789-96. doi:10.1172/jci112376
  226. Hemilä H, Kaprio J, Albanes D, Heinonen OP, Virtamo J. Vitamin C, vitamin E, and beta-carotene in relation to common cold incidence in male smokers. Epidemiology (Cambridge, Mass). Jan 2002;13(1):32-7. doi:10.1097/00001648-200201000-00006
  227. Hemilä H. Vitamin E administration may decrease the incidence of pneumonia in elderly males. Clin Interv Aging. 2016;11:1379-1385. doi:10.2147/cia.S114515
  228. Sharma M, Anderson SA, Schoop R, Hudson JB. Induction of multiple pro-inflammatory cytokines by respiratory viruses and reversal by standardized Echinacea, a potent antiviral Herbal extract. Antiviral research. Aug 2009;83(2):165-70. doi:10.1016/j.antiviral.2009.04.009
  229. Rauš K, Pleschka S, Klein P, Schoop R, Fisher P. Effect of an Echinacea-Based Hot Drink Versus Oseltamivir in Influenza Treatment: A Randomized, Double-Blind, Double-Dummy, Multicenter, Noninferiority Clinical Trial. Current therapeutic research, clinical and experimental. Dec 2015;77:66-72. doi:10.1016/j.curtheres.2015.04.001
  230. Read SA, Obeid S, Ahlenstiel C, Ahlenstiel G. The Role of Zinc in Antiviral Immunity. Adv Nutr. Jul 1 2019;10(4):696-710. doi:10.1093/advances/nmz013
  231. Wang MX, Win SS, Pang J. Zinc Supplementation Reduces Common Cold Duration among Healthy Adults: A Systematic Review of Randomized Controlled Trials with Micronutrients Supplementation. Am J Trop Med Hyg. Jul 2020;103(1):86-99. doi:10.4269/ajtmh.19-0718
  232. Hemilä H, Fitzgerald JT, Petrus EJ, Prasad A. Zinc Acetate Lozenges May Improve the Recovery Rate of Common Cold Patients: An Individual Patient Data Meta-Analysis. Open forum infectious diseases. Spring 2017;4(2):ofx059. doi:10.1093/ofid/ofx059
  233. Singh M, Das RR. Zinc for the common cold. Cochrane Database Syst Rev. Jun 18 2013;(6):Cd001364. doi:10.1002/14651858.CD001364.pub4
  234. Kardos P, Malek FA. Common Cold - an Umbrella Term for Acute Infections of Nose, Throat, Larynx and Bronchi. Pneumologie (Stuttgart, Germany). Apr 2017;71(4):221-226. Erkältung – ein Sammelbegriff für akute Infektionen von Nase, Rachen, Kehlkopf und Bronchien. doi:10.1055/s-0042-116112
  235. NaveenKumar SK, Hemshekhar M, Jagadish S, et al. Melatonin restores neutrophil functions and prevents apoptosis amid dysfunctional glutathione redox system. Journal of pineal research. Oct 2020;69(3):e12676. doi:10.1111/jpi.12676
  236. Huang S-H, Liao C-L, Chen S-J, et al. Melatonin possesses an anti-influenza potential through its immune modulatory effect. Journal of Functional Foods. 2019/07/01/ 2019;58:189-198. doi:
  237. Kell DB, Heyden EL, Pretorius E. The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend Against Viruses and Bacteria. Front Immunol. 2020;11:1221. doi:10.3389/fimmu.2020.01221
  238. Mikulic N, Uyoga MA, Mwasi E, et al. Iron Absorption is Greater from Apo-Lactoferrin and is Similar Between Holo-Lactoferrin and Ferrous Sulfate: Stable Iron Isotope Studies in Kenyan Infants. J Nutr. Dec 10 2020;150(12):3200-3207. doi:10.1093/jn/nxaa226
  239. Kruzel ML, Zimecki M, Actor JK. Lactoferrin in a Context of Inflammation-Induced Pathology. Front Immunol. 2017;8:1438. doi:10.3389/fimmu.2017.01438
  240. Shin K, Wakabayashi H, Sugita C, et al. Effects of orally administered lactoferrin and lactoperoxidase on symptoms of the common cold. Int J Health Sci (Qassim). Sep-Oct 2018;12(5):44-50.
  241. Prall SP, Muehlenbein MP. DHEA Modulates Immune Function: A Review of Evidence. Vitam Horm. 2018;108:125-144. doi:10.1016/bs.vh.2018.01.023
  242. Padgett DA, Loria RM, Sheridan JF. Steroid hormone regulation of antiviral immunity. Ann N Y Acad Sci. 2000;917:935-43. doi:10.1111/j.1749-6632.2000.tb05459.x
  243. Bauer ME, Muller GC, Correa BL, Vianna P, Turner JE, Bosch JA. Psychoneuroendocrine interventions aimed at attenuating immunosenescence: a review. Biogerontology. Feb 2013;14(1):9-20. doi:10.1007/s10522-012-9412-5
  244. Yang Q, Mao Q, Liu M, et al. The inhibitory effect of dehydroepiandrosterone and its derivatives against influenza A virus in vitro and in vivo. Arch Virol. Nov 2016;161(11):3061-72. doi:10.1007/s00705-016-2993-6
  245. Loria RM. Beta-androstenes and resistance to viral and bacterial infections. Neuroimmunomodulation. 2009;16(2):88-95. doi:10.1159/000180263
  246. Padgett DA, Loria RM, Sheridan JF. Endocrine regulation of the immune response to influenza virus infection with a metabolite of DHEA-androstenediol. J Neuroimmunol. Sep 1997;78(1-2):203-11. doi:10.1016/s0165-5728(97)00102-1
  247. Degelau J, Guay D, Hallgren H. The effect of DHEAS on influenza vaccination in aging adults. J Am Geriatr Soc. Jun 1997;45(6):747-51.
  248. Huang Z, Liu Y, Qi G, Brand D, Zheng SG. Role of Vitamin A in the Immune System. J Clin Med. Sep 6 2018;7(9):258. doi:10.3390/jcm7090258
  249. Surman SL, Rudraraju R, Sealy R, Jones B, Hurwitz JL. Vitamin A deficiency disrupts vaccine-induced antibody-forming cells and the balance of IgA/IgG isotypes in the upper and lower respiratory tract. Viral Immunol. Aug 2012;25(4):341-4. doi:10.1089/vim.2012.0023
  250. Penkert RR, Smith AP, Hrincius ER, et al. Vitamin A deficiency dysregulates immune responses toward influenza virus and increases mortality after bacterial coinfections. J Infect Dis. Sep 22 2020;doi:10.1093/infdis/jiaa597
  251. Penkert RR, Cortez V, Karlsson EA, et al. Vitamin A Corrects Tissue Deficits in Diet-Induced Obese Mice and Reduces Influenza Infection After Vaccination and Challenge. Obesity (Silver Spring). Sep 2020;28(9):1631-1636. doi:10.1002/oby.22929
  252. Liang Y, Yi P, Wang X, et al. Retinoic Acid Modulates Hyperactive T Cell Responses and Protects Vitamin A-Deficient Mice against Persistent Lymphocytic Choriomeningitis Virus Infection. J Immunol. Jun 1 2020;204(11):2984-2994. doi:10.4049/jimmunol.1901091
  253. Ahmad SM, Alam MJ, Khanam A, et al. Vitamin A Supplementation during Pregnancy Enhances Pandemic H1N1 Vaccine Response in Mothers, but Enhancement of Transplacental Antibody Transfer May Depend on When Mothers Are Vaccinated during Pregnancy. J Nutr. Dec 1 2018;148(12):1968-1975. doi:10.1093/jn/nxy228
  254. Patel N, Penkert RR, Jones BG, et al. Baseline Serum Vitamin A and D Levels Determine Benefit of Oral Vitamin A&D Supplements to Humoral Immune Responses Following Pediatric Influenza Vaccination. Viruses. Sep 30 2019;11(10)doi:10.3390/v11100907
  255. Sundaram ME, Meydani SN, Vandermause M, Shay DK, Coleman LA. Vitamin E, vitamin A, and zinc status are not related to serologic response to influenza vaccine in older adults: an observational prospective cohort study. Nutr Res. Feb 2014;34(2):149-54. doi:10.1016/j.nutres.2013.12.004
  256. Kartasurya MI, Ahmed F, Subagio HW, Rahfiludin MZ, Marks GC. Zinc combined with vitamin A reduces upper respiratory tract infection morbidity in a randomised trial in preschool children in Indonesia. The British journal of nutrition. Dec 28 2012;108(12):2251-60. doi:10.1017/s0007114512000499
  257. Arreola R, Quintero-Fabián S, López-Roa RI, et al. Immunomodulation and anti-inflammatory effects of garlic compounds. J Immunol Res. 2015;2015:401630. doi:10.1155/2015/401630
  258. Nakamoto M, Kunimura K, Suzuki JI, Kodera Y. Antimicrobial properties of hydrophobic compounds in garlic: Allicin, vinyldithiin, ajoene and diallyl polysulfides. Experimental and therapeutic medicine. Feb 2020;19(2):1550-1553. doi:10.3892/etm.2019.8388
  259. Rouf R, Uddin SJ, Sarker DK, et al. Antiviral potential of garlic (Allium sativum) and its organosulfur compounds: A systematic update of pre-clinical and clinical data. Trends Food Sci Technol. Oct 2020;104:219-234. doi:10.1016/j.tifs.2020.08.006
  260. Percival SS. Aged Garlic Extract Modifies Human Immunity. J Nutr. Feb 2016;146(2):433s-436s. doi:10.3945/jn.115.210427
  261. Ippolito E, Belcaro G, Luzzi R, et al. Robuvit®: improvement of fatigue in medical convalescence. The Journal of sports medicine and physical fitness. May 2018;58(5):678-683. doi:10.23736/s0022-4707.17.08158-0